Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 2/20 | 0.35 |
| ▸ | TDP2 | O95551 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GALK1 | P51570 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL3903553 | 1.00 | DNMT1 (0.42) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL10680234 | 0.98 | DNMT1 (0.41) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL9678206 | 0.95 | DNMT1 (0.39) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8848720 | 0.95 | DNMT1 (0.39) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL23087090 | 0.93 | DNMT1 (0.38) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL21805756 | 0.93 | MAPT (0.39) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL21625776 | 0.93 | MAPT (0.41) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL20515128 | 0.93 | DNMT1 (0.40) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL3650047 | 0.93 | DNMT1 (0.40) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL7064057 | 0.93 | DNMT1 (0.40) | DNMT1MAPTHTTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1231 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3827814-B1 | OPHTHALMIC FORMULATIONS | DOMPE FARM SPA (IT) | 2025-12-17 | — | — | EP | claimed |
| WO-2025222268-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2022157373-A1 | COMPOSITIONS AND KITS FOR IN VIVO IMAGING OF CARDIAC SARCOIDOSIS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-07-28 | — | — | WO | claimed |
| CN-114133635-A | Oxidation and corrosion resistant plastic | 江苏爱唯生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-106442039-B | Device, solution and method for sample collection | 阿博根公司 | 2020-08-07 | — | — | CN | claimed |
| CN-107486037-B | A kind of PVDF/PDA composite membrane with super hydrophilicity | 福州大学 | 2019-11-12 | — | — | CN | claimed |
| CN-107486037-A | A kind of PVDF/PDA composite membranes with super hydrophilicity | 福州大学 | 2017-12-19 | — | — | CN | claimed |
| US-20170087089-A1 | PROCESS FOR THE PREPARATION OF UNILAMELLAR LIPOSOMAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2017-03-30 | — | — | US | claimed |
| US-8217024-B2 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-1971325-A2 | CONJUGATED ESTROGEN COMPOSITIONS, APPLICATORS, KITS, AND METHODS OF MAKING AND USE THEREOF | Duramed Pharmaceuticals, Inc. (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070191321-A1 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. | 2007-08-16 | — | — | US | claimed |
| WO-2007076144-A2 | CONJUGATED ESTROGEN COMPOSITIONS, APPLICATORS, KITS, AND METHODS OF MAKING AND USE THEREOF | DURAMED PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| EP-0034213-B1 | A STABILIZED AQUEOUS COENZYME SOLUTION FOR USE IN A CLINICAL ASSAY, A METHOD OF STABILIZING A LABILE COENZYME IN AN AQUEOUS CLINICAL ASSAY SOLUTION AND A KIT FOR USE IN SAID CLINICAL ASSAY | Modrovich, Ivan Endre (US) | 1984-11-07 | — | — | EP | claimed |
| US-4394449-A | REGENERATION OF COENZYME FOR CLINICAL ASSAYS | MEDICAL ANALYSIS SYSTEMS, INC. | 1983-07-19 | — | — | US | claimed |
| EP-0034213-A1 | A stabilized aqueous coenzyme solution for use in a clinical assay, a method of stabilizing a labile coenzyme in an aqueous clinical assay solution and a kit for use in said clinical assay | Modrovich, Ivan Endre (US) | 1981-08-26 | — | — | EP | claimed |
| JP-8049282-A | — | — | None | — | — | JP | disclosed |
| EP-4730479-A2 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | Kyoto University (JP) | 2026-04-22 | — | — | EP | disclosed |
| EP-4089406-B1 | ION SENSOR | SYSMEX CORP (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4441079-B1 | SWITCHABLE POLYPEPTIDE AND ITS USE FOR GENTLE AFFINITY PURIFICATION | UNIV OXFORD INNOVATION LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250381246-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250380724-A1 | METHOD FOR PRODUCING PROCESSED PLANT PROTEIN-CONTAINING COMPOSITION | AMANO ENZYME INC. (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-3827814-B1 | OPHTHALMIC FORMULATIONS | DOMPE FARM SPA (IT) | 2025-12-17 | — | — | EP | disclosed |
| US-20250354996-A1 | SIGNAL AMPLIFICATION AND MULTIPLEXING USING MASS TAGS FOR IA-LC-MS/ MS BASED ASSAYS | GENENTECH, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250352677-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LTD (GB) | 2025-11-20 | — | — | US | disclosed |
| WO-2025233688-A1 | MICROPLATE-BASED ELECTROPHORESIS SYSTEM | AXOR BIOSYSTEMS INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025222280-A1 | STABLE TOPICAL COMPOSITIONS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025222268-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325679-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA | 89BIO INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12447192-B1 | Stable cannabinoid-comprising nanoemulsions and methods of using the same | SGN NANOPHARMA INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4619755-A1 | SIGNAL AMPLIFICATION AND MULTIPLEXING USING MASS TAGS FOR IA-LC-MS/MS BASED ASSAYS | Genentech, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12411103-B2 | Electrode, method for manufacturing electrode, ion sensor, in-vivo component measuring device, and in-vivo component measuring method | SYSMEX CORPORATION (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250246685-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | KYOTO UNIVERSITY (JP) | 2025-07-31 | — | — | US | disclosed |
| US-12371521-B2 | Photosensitive composition, hologram recording medium using the same, hologram optical element, and method of forming hologram diffraction grating | Sony Group Corporation (JP) | 2025-07-29 | — | — | US | disclosed |
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89BIO, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4577563-A2 | METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89Bio, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12345718-B2 | Method for determining the haemoglobin content of an erythroid cell | UNIVERSITÉ PARIS EST CRÉTEIL VAL DE MARNE (FR) | 2025-07-01 | — | — | US | disclosed |
| CN-120202411-A | Signal amplification and multiplexing for IA-LC-MS/MS based assays using mass labels | 基因泰克公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250170249-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA | 89BIO, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250161331-A1 | ANTI-INFLAMMATORY DRUG-CANNABINOID-COMPRISING NANOEMULSIONS AND METHODS OF USING THE SAME | SGN NANOPHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4548771-A1 | METHOD FOR PRODUCING PROCESSED PLANT PROTEIN-CONTAINING COMPOSITION | Amano Enzyme Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4543479-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA | 89Bio, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119816317-A | Compositions and methods for treating severe hypertriglyceridemia | 89生物公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250108136-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2025-04-03 | — | — | US | disclosed |
| US-20250082615-A1 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LIMITED (IN) | 2025-03-13 | — | — | US | disclosed |
| WO-2025043155-A1 | THERAPEUTIC REGIMENS AND METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89BIO, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119451579-A | Method for producing processed plant protein-containing composition | 天野酶制品株式会社 | 2025-02-14 | — | — | CN | disclosed |
| CN-119367551-A | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89生物公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250002528-A1 | SWITCHABLE POLYPEPTIDE AND ITS USE FOR GENTLE AFFINITY PURIFICATION | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-01-02 | — | — | US | disclosed |
| EP-4482485-A1 | ANTI-INFLAMMATORY DRUG-CANNABINOID-COMPRISING NANOEMULSIONS AND METHODS OF USING THE SAME | SGN Nanopharma Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-112472796-B | Methods of diagnosing or treating neurological disorders using P75ECD and/or P75 | 上海澳宗生物科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240415929-A1 | FORMULATIONS COMPRISING A TRIS BUFFER AND A PROTEIN | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-3535589-B1 | METHOD FOR DETERMINING THE HEMOGLOBIN F CONTENT OF AN ERYTHROID CELL | UNIV PARIS VAL DE MARNE (FR) | 2024-12-04 | — | — | EP | disclosed |
| CN-117120070-B | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89生物公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4441079-A1 | SWITCHABLE POLYPEPTIDE AND ITS USE FOR GENTLE AFFINITY PURIFICATION | Oxford University Innovation Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4058059-B1 | NANOEMULSION COMPOSITIONS FOR TREATING AEROALLERGEN ASSOCIATED ALLERGY AND INFLAMMATION | UNIV MICHIGAN REGENTS (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12109277-B2 | Methods and kits for preparing radionuclide complexes | THERAGNOSTICS LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-114870061-B | Air spray based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12098168-B2 | XylR mutant for improved xylose utilization or improved co-utilization of glucose and xylose preliminary | GENOMATICA, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240307492-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4428982-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | Kyoto University (JP) | 2024-09-11 | — | — | EP | disclosed |
| US-20240252620-A1 | COMBINED AGONIST ADJUVANT FOR CORONAVIRUS VACCINE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-08-01 | — | — | US | disclosed |
| CN-118406674-A | DNA repair enzyme extraction method | 杭州合碳创物科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118389457-A | Peptide ligase and use thereof | 牛津大学创新有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-12036293-B2 | Methods and kits for preparing radionuclide complexes | THERAGNOSTICS LIMITED (GB) | 2024-07-16 | — | — | US | disclosed |
| US-12036284-B2 | Compositions and methods of treatment for severe hypertriglyceridemia | 89BIO, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240165277-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| WO-2024108178-A1 | SIGNAL AMPLIFICATION AND MULTIPLEXING USING MASS TAGS FOR IA-LC-MS/MS BASED ASSAYS | GENENTECH, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-110582566-B | Peptide ligase and use thereof | 牛津大学创新有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024044680-A2 | METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89BIO, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3843701-B1 | BACTERIOCINS TO IMPROVE VAGINAL COLONIZATION OF HYDROGEN PEROXIDE PRODUCING LACTOBACILLUS FOR FEMALE REPRODUCTIVE HEALTH | OSEL INC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240042016-A1 | NANOEMULSION VACCINE COMPOSITIONS AND METHODS FOR SUPPRESSING REACTIVITY TO MULTIPLE FOOD ALLERGENS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-02-08 | — | — | US | disclosed |
| EP-4304625-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89Bio, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024010056-A1 | SECONDARY BATTERY | ダイキン工業株式会社 | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010057-A1 | NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL | ダイキン工業株式会社 | 2024-01-11 | — | — | WO | disclosed |
| CN-110545845-B | anti-CD 33 antibody agents | 纪念斯隆凯特琳癌症中心 | 2024-01-05 | — | — | CN | disclosed |
| WO-2024004947-A1 | METHOD FOR PRODUCING PROCESSED PLANT PROTEIN-CONTAINING COMPOSITION | 天野エンザイム株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023249003-A1 | SURFACE TREATMENT AGENT FOR ELECTRODE MATERIAL, POSITIVE ELECTRODE ACTIVE MATERIAL, CURRENT COLLECTOR FOIL, NEGATIVE ELECTRODE ACTIVE MATERIAL, CONDUCTIVE AID, ELECTRODE, BATTERY, METHOD FOR MANUFACTURING POSITIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CURRENT COLLECTOR FOIL, METHOD FOR MANUFACTURING NEGATIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CONDUCTIVE AID, AND METHOD FOR MANUFACTURING ELECTRODE | ダイキン工業株式会社 | 2023-12-28 | — | — | WO | disclosed |
| US-20230414768-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA | 89BIO, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023250493-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA | 89BIO INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11850275-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89BIO, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023232096-A1 | AIR SPRAY BASED ON VIRUS BLOCKING AGENT, AND USE THEREOF | 康码（上海）生物科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| US-11826436-B2 | Methods and kits for preparing radionuclide complexes | THERAGNOSTICS LIMITED (GB) | 2023-11-28 | — | — | US | disclosed |
| CN-117120070-A | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89生物公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117100874-A | Nanoparticle, preparation and application thereof, eye disease medicine comprising nanoparticle and preparation thereof | 苏州维益生物科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4271406-A1 | NANOEMULSION VACCINE COMPOSITIONS AND METHODS FOR SUPPRESSING REACTIVITY TO MULTIPLE FOOD ALLERGENS | The Regents of The University of Michigan (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230338471-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230330202-A1 | NANOEMULSION AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-19 | — | — | US | disclosed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230288429-A1 | REAL TIME ELECTRONIC CELL SENSING SYSTEMS AND APPLICATIONS FOR CELL-BASED ASSAYS | AGILENT TECHNOLOGIES, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023133143-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023099876-A1 | SWITCHABLE POLYPEPTIDE AND ITS USE FOR GENTLE AFFINITY PURIFICATION | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| CN-113274355-B | Rifampicin solid dispersion | 鲁平有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230145666-A1 | REAL TIME ELECTRONIC CELL SENSING SYSTEMS AND APPLICATIONS FOR CELL-BASED ASSAYS | AGILENT TECHNOLOGIES, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023079988-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | 国立大学法人京都大学 | 2023-05-11 | — | — | WO | disclosed |
| US-11642405-B2 | Nanoemulsion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2023-05-09 | — | — | US | disclosed |
| US-11604197-B2 | Real time electronic cell sensing systems and applications for cell-based assays | AGILENT TECHNOLOGIES, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-11596669-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89BIO, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11571458-B2 | Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health | OSEL, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230011185-A1 | LAMINATE, METHOD FOR MANUFACTURING LAMINATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-01-12 | — | — | US | disclosed |
| WO-2023276380-A1 | ION SENSOR, METHOD FOR MANUFACTURING ION SENSOR, AND METHOD FOR MEASURING ION | シスメックス株式会社 | 2023-01-05 | — | — | WO | disclosed |
| US-20220387316-A1 | NANOEMULSION COMPOSITIONS FOR TREATING AEROALLERGEN ASSOCIATED ALLERGY AND INFLAMMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022251406-A1 | COMBINED AGONIST ADJUVANT FOR CORONAVIRUS VACCINE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4089406-A1 | ELECTRODE, ELECTRODE MANUFACTURING METHOD, ION SENSOR, IN VIVO COMPONENT MEASURING DEVICE, AND IN VIVO COMPONENT MEASURING METHOD | SYSMEX CORPORATION (JP) | 2022-11-16 | — | — | EP | disclosed |
| US-20220339304-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| US-20220334077-A1 | ELECTRODE, METHOD FOR MANUFACTURING ELECTRODE, ION SENSOR, IN-VIVO COMPONENT MEASURING DEVICE, AND IN-VIVO COMPONENT MEASURING METHOD | SYSMEX CORPORATION (JP) | 2022-10-20 | — | — | US | disclosed |
| CN-115181616-A | Nucleic acid scavenger based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-115119829-A | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles | 斯特雷克股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022203074-A1 | FLUORINE-CONTAINING CYCLIC SULFONYLIMIDE SALT, AND METHOD FOR PRODUCING SAME, NON-AQUEOUS ELECTROLYTE, NON-AQUEOUS SECONDARY BATTERY | 旭化成株式会社 | 2022-09-29 | — | — | WO | disclosed |
| CN-111635752-B | Gold nanorod/DNA/carbon dot nano hybrid material and preparation method and application thereof | 中国科学院理化技术研究所 | 2022-09-23 | — | — | CN | disclosed |
| US-20220296678-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298523-A1 | GENETICALLY MODIFIED PLANTS AND METHODS OF MAKING THE SAME | Empyrean Neuroscience, Inc. | 2022-09-22 | — | — | US | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058059-A1 | NANOEMULSION COMPOSITIONS FOR TREATING AEROALLERGEN ASSOCIATED ALLERGY AND INFLAMMATION | The Regents Of The University Of Michigan (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022192601-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220282657-A1 | ADJUVANT COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114929271-A | Nanoemulsion compositions for the treatment of aeroallergen-related allergies and inflammation | 密歇根大学董事会 | 2022-08-19 | — | — | CN | disclosed |
| EP-4043502-A1 | PHOTOPOLYMERIZABLE HOE COMPOSITION | Xetos AG (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-4043961-A1 | 2K SYSTEM | Xetos AG (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-4043962-A1 | PHOTOPOLYMERIZABLE COMPOSITION | Xetos AG (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-114870061-A | Air spray based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220242985-A1 | PHOTOSENSITIVE COMPOSITION, HOLOGRAM RECORDING MEDIUM USING THE SAME, HOLOGRAM OPTICAL ELEMENT, AND METHOD OF FORMING HOLOGRAM DIFFRACTION GRATING | Sony Group Corporation (JP) | 2022-08-04 | — | — | US | disclosed |
| WO-2022156908-A1 | METHOD FOR PREPARING A LYOPHILIZED COMPOSITION | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022156907-A1 | METHOD AND KIT FOR LABELING A BIOMOLECULE WITH ONE OR MORE DETECTABLE LABELS, INCLUDING A RADIOLABEL | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022157373-A1 | COMPOSITIONS AND KITS FOR IN VIVO IMAGING OF CARDIAC SARCOIDOSIS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022153616-A1 | HOLOGRAM RECORDING MEDIUM, HOLOGRAM OPTICAL ELEMENT, OPTICAL DEVICE, OPTICAL COMPONENT, AND METHOD FOR FORMING HOLOGRAM DIFFRACTION GRATING | ソニーグループ株式会社 | 2022-07-21 | — | — | WO | disclosed |
| WO-2022145446-A1 | CHLORINATED POLYOLEFIN COMPOSITION | 昭和電工株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022145447-A1 | CHLORINATED-POLYOLEFIN COMPOSITION | 昭和電工株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147173-A1 | NANOEMULSION VACCINE COMPOSITIONS AND METHODS FOR SUPPRESSING REACTIVITY TO MULTIPLE FOOD ALLERGENS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022138893-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY | ＭＵアイオニックソリューションズ株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022124382-A1 | PROVIDED ARE A NEGATIVE ELECTRODE MATERIAL IN A CONTAINER, A TRANSPORTATION METHOD FOR NEGATIVE ELECTRODE MATERIAL, A NEGATIVE ELECTRODE MATERIAL STORAGE CONTAINER, A STORAGE METHOD FOR NEGATIVE ELECTRODE MATERIAL, AND A MANUFACTURING METHOD FOR NEGATIVE ELECTRODE MATERIAL. | 昭和電工マテリアルズ株式会社 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022123701-A1 | PACKED NEGATIVE ELECTRODE MATERIAL, NEGATIVE ELECTRODE MATERIAL TRANSPORTATION METHOD, NEGATIVE ELECTRODE MATERIAL STORAGE CONTAINER, AND NEGATIVE ELECTRODE MATERIAL STORAGE METHOD | 昭和電工マテリアルズ株式会社 | 2022-06-16 | — | — | WO | disclosed |
| EP-2417249-B1 | DNA-CELL CONJUGATES | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022107255-A1 | LITHIUM ION SECONDARY BATTERY AND SEPARATION MEMBRANE | 昭和電工マテリアルズ株式会社 | 2022-05-27 | — | — | WO | disclosed |
| WO-2022102623-A1 | METHOD AND KIT FOR TRANSPARENTIZING BIOLOGICAL MATERIAL | 住友化学株式会社 | 2022-05-19 | — | — | WO | disclosed |
| EP-3998289-A1 | PHOTOSENSITIVE COMPOSITION AND A HOLOGRAM STORAGE MEDIUM USING SAME, HOLOGRAM OPTICAL ELEMENT, AND HOLOGRAM DIFFRACTION GRATING FORMING METHOD | Sony Group Corporation (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20220105172-A1 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022054737-A1 | FLUORINATED CARBOXYLIC ACID SALT COMPOUND | ダイキン工業株式会社 | 2022-03-17 | — | — | WO | disclosed |
| WO-2022045282-A1 | POLYMERIZATION CATALYST COMPOSITION, METHOD FOR PRODUCING POLYMERIZATION CATALYST COMPOSITION, AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER | DIC株式会社 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022045059-A1 | RESIN COMPOSITION, CURED PRODUCT, MULTILAYER BODY, METHOD FOR PRODUCING CURED PRODUCT, AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2022-03-03 | — | — | WO | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11231427-B2 | Method for determining the haemoglobin F content of an erythroid cell | UNIVERSITE PARIS EST CRETEIL VAL DE MARNE (FR) | 2022-01-25 | — | — | US | disclosed |
| US-20210353713-A1 | FORMULATIONS COMPRISING A TRIS BUFFER AND A PROTEIN | AMGEN INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| EP-3010501-B1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3610005-B1 | PEPTIDE LIGASE AND USE THEREOF | UNIV OXFORD INNOVATION LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-11120993-B2 | Diffusing agent composition and method of manufacturing semiconductor substrate | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20210275628-A1 | BACTERIOCINS TO IMPROVE VAGINAL COLONIZATION OF HYDROGEN PEROXIDE PRODUCING LACTOBACILLUS FOR FEMALE REPRODUCTIVE HEALTH | OSEL, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210275557-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-09-09 | — | — | US | disclosed |
| CN-106794222-B | Methods of diagnosing or treating neurological disorders using P75ECD and/or P75 | 苏州澳宗生物科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113274355-A | Rifaximin solid dispersion | 鲁平有限公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2021140933-A1 | ELECTRODE, ELECTRODE MANUFACTURING METHOD, ION SENSOR, IN VIVO COMPONENT MEASURING DEVICE, AND IN VIVO COMPONENT MEASURING METHOD | シスメックス株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3843701-A2 | BACTERIOCINS TO IMPROVE VAGINAL COLONIZATION OF HYDROGEN PEROXIDE PRODUCING LACTOBACILLUS FOR FEMALE REPRODUCTIVE HEALTH | Osel, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-11046746-B2 | Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein | SUZHOU AUZONE BIOLOGICAL TECHNOLOGY CO., LTD | 2021-06-29 | — | — | US | disclosed |
| CN-110218778-B | PCR reaction system, reagent, kit and PCR method | 珠海宝锐生物科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021095574-A1 | ELECTRODE AND ELECTROCHEMICAL DEVICE | ダイキン工業株式会社 | 2021-05-20 | — | — | WO | disclosed |
| US-20210138094-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| CN-112638970-A | Polyurethane resin composition and method for insulating building | 株式会社日本雅克 | 2021-04-09 | — | — | CN | disclosed |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-30 | — | — | US | disclosed |
| CN-112472796-A | Methods of diagnosing or treating neurological disorders using P75ECD and/or P75 | 苏州澳宗生物科技有限公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2021020020-A1 | ADDITIVE COMPOSITION | 株式会社ADEKA | 2021-02-04 | — | — | WO | disclosed |
| US-10889622-B2 | Peptide ligase and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| US-20200375959-A1 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LIMITED (IN) | 2020-12-03 | — | — | US | disclosed |
| US-20200373162-A1 | DIFFUSING AGENT COMPOSITION AND METHOD OF MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3273982-B1 | METHOD OF DIAGNOSIS OR TREATMENT OF NEUROLOGICAL DISORDERS WITH P75ECD AND/OR P75 | SUZHOU AUZONE BIOLOGICAL TECH CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020218321-A1 | WATER-SOLUBLE FILM AND PACKAGING | 株式会社クラレ | 2020-10-29 | — | — | WO | disclosed |
| US-10809222-B2 | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020184650-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, LENS, AND METHOD FOR MANUFACTURING OPTICAL MEMBER | 富士フイルム株式会社 | 2020-09-17 | — | — | WO | disclosed |
| CN-111635752-A | Gold nanorod/DNA/carbon dot nano hybrid material and preparation method and application thereof | 中国科学院理化技术研究所 | 2020-09-08 | — | — | CN | disclosed |
| US-10716770-B2 | Nicotinic receptor non-competitive antagonists | CATALYST BIOSCIENCES, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3653733-A1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | Aragon Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200115422-A1 | PEPTIDE LIGASE AND USE THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| EP-3268337-B1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| WO-2020047203-A2 | BACTERIOCINS TO IMPROVE VAGINAL COLONIZATION OF HYDROGEN PEROXIDE PRODUCING LACTOBACILLUS FOR FEMALE REPRODUCTIVE HEALTH | OSEL, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | UNIVERSITY OF HEIDELBERG (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-107438615-B | Method and kit for preparing radionuclide complexes | 施拉格诺斯迪克斯有限公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-3611256-A1 | APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE | Universität Heidelberg (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3610005-A1 | PEPTIDE LIGASE AND USE THEREOF | Oxford University Innovation Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-10549259-B2 | Carbide derived carbon for use in chemical scrubbers | BAE SYSTEMS INFORMATION AND ELECTRONIC SYSTEMS INTEGRATION INC. (US) | 2020-02-04 | — | — | US | disclosed |
| CN-110582566-A | Peptide ligase and uses thereof | 牛津大学创新有限公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-110545845-A | anti-CD 33 antibody agents | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-12-06 | — | — | CN | disclosed |
| EP-2734512-B1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | BIOELECTRON TECH CORP (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-11-19 | — | — | US | disclosed |
| CN-107486037-B | A kind of PVDF/PDA composite membrane with super hydrophilicity | 福州大学 | 2019-11-12 | — | — | CN | disclosed |
| EP-2877599-B1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | ARAGON PHARMACEUTICALS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019189413-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ENERGY DEVICE USING SAME | 三菱ケミカル株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019188207-A1 | ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, MODULE AND COMPOUND | ダイキン工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019189414-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME | 三菱ケミカル株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019181240-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | ダイキン工業株式会社 | 2019-09-26 | — | — | WO | disclosed |
| EP-3535589-A1 | METHOD FOR DETERMINING THE HAEMOGLOBIN F CONTENT OF AN ERYTHROID CELL | Université Paris-Est Créteil Val de Marne (FR) | 2019-09-11 | — | — | EP | disclosed |
| US-20190254991-A1 | Nicotinic Receptor Non-Competitive Antagonists | CATALYST BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| CN-107353304-B | Phosphoric acid safe ground azoles amine trishydroxymethylaminomethane salt and its crystal form A, preparation method and application | 浙江普洛得邦制药有限公司 | 2019-08-13 | — | — | CN | disclosed |
| WO-2019150823-A1 | COMPOSITION, FILM, LAMINATE STRUCTURE, LIGHT-EMITTING DEVICE, AND DISPLAY | 住友化学株式会社 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019150896-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | ダイキン工業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019150895-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | ダイキン工業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| EP-3515427-A2 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | Qingdao Primedicine Pharmaceutical Co., Ltd (CN) | 2019-07-31 | — | — | EP | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| CN-109996539-A | N-methyl-D-aspartate receptor allosteric modulators and its application method | 青岛普美圣医药科技有限公司 | 2019-07-09 | — | — | CN | disclosed |
| EP-2791133-B1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10258582-B2 | Nicotinic receptor non-competitive antagonists | CATALYST BIOSCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10227334-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| CN-107414069-B | Silver nanoparticle disk, preparation method and Gin Nanometer globoid and assembly using its preparation | 国家纳米科学中心 | 2019-03-12 | — | — | CN | disclosed |
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| US-10202325-B2 | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-02-12 | — | — | US | disclosed |
| CN-105451735-B | azetidine estrogen receptor modulators and uses thereof | 西拉根制药公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-105324115-B | estrogen receptor modulators and uses thereof | 赛拉根医药股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109071482-A | Carry the flavonoids type compound of O- rhamnopyranosyl residue | 汉堡大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-109072271-A | The method for being used to prepare rhamnopyranosyl flavonoids | 汉堡大学 | 2018-12-21 | — | — | CN | disclosed |
| US-10151697-B2 | Two-color fluorescence localization super-resolution biological microscopy method and system | SHENZHEN NANOBIOIMAGING LIMITED (CN) | 2018-12-11 | — | — | US | disclosed |
| EP-3010502-B1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2493456-B1 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LTD (IN) | 2018-11-21 | — | — | EP | disclosed |
| US-20180319730-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2018189517-A1 | PEPTIDE LIGASE AND USE THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10100308-B2 | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180287146-A1 | LITHIUM POWDER, LITHIUM ION SECONDARY BATTERY NEGATIVE ELECTRODE USING THE SAME, AND LITHIUM ION SECONDARY BATTERY USING THE LITHIUM ION SECONDARY BATTERY NEGATIVE ELECTRODE | TDK CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180271806-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | CATALYST BIOSCIENCES, INC. | 2018-09-27 | — | — | US | disclosed |
| CN-105121413-B | Polycyclic estrogen receptor modulators and uses thereof | 赛拉根医药股份有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3354650-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-08-01 | — | — | EP | disclosed |
| US-10029971-B2 | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-07-24 | — | — | US | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3337855-A1 | FLAME-RETARDANT THERMOPLASTIC POLYURETHANE | BASF SE (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3337850-A1 | FLAME-RETARDANT THERMOPLASTIC POLYURETHANE | BASF SE (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170996-A1 | METHOD OF DIAGNOSIS OR TREATMENT OF NEUROLOGICAL DISORDERS WITH P75ECD AND/OR P75 | SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170922-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-21 | — | — | US | disclosed |
| US-9969970-B2 | DNA-cell conjugates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-15 | — | — | US | disclosed |
| CN-107907399-A | A kind of preparation method for the mountant that can mark nucleus at the same time | 遵义医学院 | 2018-04-13 | — | — | CN | disclosed |
| EP-3303326-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20180092996-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| EP-2718309-B1 | TRANSCRIPTION FACTOR MODULATING TERPENE BIOSYNTHESIS | KEYGENE NV (NL) | 2018-04-04 | — | — | EP | disclosed |
| US-9932388-B2 | Chromatographic process for producing high purity fibrinogen and thrombin | HEMARUS THERAPEUTICS LIMITED (IN) | 2018-04-03 | — | — | US | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| CN-107735026-A | The method for measuring tear component in ocular fluid samples | 黛尔格诺斯蒂尔有限公司 | 2018-02-23 | — | — | CN | disclosed |
| EP-3273982-A1 | METHOD OF DIAGNOSIS OR TREATMENT OF NEUROLOGICAL DISORDERS WITH P75ECD AND/OR P75 | Fujian Tiantai Medical Technology Co. Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
| US-9873684-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3268337-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | Theragnostics Limited (GB) | 2018-01-17 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9855270-B2 | Methods and compositions for modulating estrogen receptor mutants | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| CN-107531722-A | Heterocyclic estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107486037-A | A kind of PVDF/PDA composite membranes with super hydrophilicity | 福州大学 | 2017-12-19 | — | — | CN | disclosed |
| CN-105008343-B | Alternatively benzothiophene derivative of property ERs degradation agent and combinations thereof | 诺华股份有限公司 | 2017-12-08 | — | — | CN | disclosed |
| EP-2376485-B1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-107438615-A | For preparing the method and kit of radionuclide complex compound | 施拉格诺斯迪克斯有限公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-107414069-A | Silver nanoparticle disk, its preparation method and the Gin Nanometer globoid and assembly using its preparation | 国家纳米科学中心 | 2017-12-01 | — | — | CN | disclosed |
| US-20170335293-A1 | Modified Luciferases And Uses Thereof | TARGETING SYSTEMS | 2017-11-23 | — | — | US | disclosed |
| CN-107353304-A | Phosphoric acid safe ground azoles amine trishydroxymethylaminomethane salt and its crystal formation A, preparation method and application | 浙江普洛得邦制药有限公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-104515760-B | Two Colour Fluorescence positions super-resolution biology microscope method and system | 深圳市纳观生物有限公司 | 2017-10-31 | — | — | CN | disclosed |
| US-20170297991-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | PTC THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170292128-A1 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-12 | — | — | US | disclosed |
| US-20170284941-A1 | TWO-COLOR FLUORESCENCE LOCALIZATION SUPER-RESOLUTION BIOLOGICAL MICROSCOPY METHOD AND SYSTEM | NINGBO INVIEW INTELLIGENT TECHNOLOGY CO., LTD (CN) | 2017-10-05 | — | — | US | disclosed |
| US-20170275273-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170247713-A1 | TRICHOME-SPECIFIC TRANSCRIPTION FACTOR MODULATING TERPENE BIOSYNTHESIS | KEYGENE N.V. (NL) | 2017-08-31 | — | — | US | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9732328-B2 | Modified luciferases and uses thereof | TARGETING SYSTEMS (US) | 2017-08-15 | — | — | US | disclosed |
| CN-106983749-A | Androgen receptor modifier and application thereof | 亚拉冈制药公司 | 2017-07-28 | — | — | CN | disclosed |
| US-20170196840-A1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | ARAGON PHARMACEUTICALS INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-9689018-B2 | Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses | DIAGNOSTIC HYBRIDS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| CN-106831755-A | Benzamide compound and its salt form and purposes | 阿腾弩阿公司 | 2017-06-13 | — | — | CN | disclosed |
| US-9670264-B2 | Water soluble G-protein coupled receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170151204-A1 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE | UNIVERSITé LAVAL (CA) | 2017-06-01 | — | — | US | disclosed |
| CN-106794222-A | Methods of diagnosing or treating neurological disorders using P75ECD and/or P75 | 福建天泰医药科技有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9655880-B2 | Azetidine estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| CN-103724322-B | Androgen receptor modulators and uses thereof | 亚拉冈制药公司 | 2017-05-03 | — | — | CN | disclosed |
| US-9617602-B2 | Methods and compositions for determining resistance to androgen receptor therapy | ARAGON PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3150196-A1 | PROCESS FOR THE PREPARATION OF UNILAMELLAR LIPOSOMAL COMPOSITION | Sun Pharma Advanced Research Company Ltd (IN) | 2017-04-05 | — | — | EP | disclosed |
| US-20170087089-A1 | PROCESS FOR THE PREPARATION OF UNILAMELLAR LIPOSOMAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2017-03-30 | — | — | US | disclosed |
| CN-106518856-A | Pyrazine derivatives useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9598473-B2 | Trichome-specific transcription factor modulating terpene biosynthesis | KEYGENE N.V. (NL) | 2017-03-21 | — | — | US | disclosed |
| US-20170071878-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | CATALYST BIOSCIENCES INC (US) | 2017-03-16 | — | — | US | disclosed |
| CN-103842563-B | Protein exhibiting expression method | 亲和生物科学公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496210-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496209-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-2576496-B1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | CATALYST BIOSCIENCES INC (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-106488767-A | Adjust the method and composition of ERs mutant | 豪夫迈·罗氏有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-9586952-B2 | Polycyclic estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-104220426-B | Estrogen receptor modulators and uses thereof | 塞拉根制药公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9567279-B2 | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols | EDISON PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3116496-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | F. Hoffmann-La Roche AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| CN-104114551-B | Fluorinated estrogen receptor modulators and uses thereof | 塞拉根制药公司 | 2017-01-18 | — | — | CN | disclosed |
| CN-101784273-B | (2S, 3R) -N- (2- ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | 阿腾弩阿公司 | 2017-01-18 | — | — | CN | disclosed |
| US-9532974-B2 | Nicotinic receptor non-competitive antagonists | TARGACEPT, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160367526-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160355508-A1 | POLYCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2016189011-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2431037-B1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | ATTENUA INC (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-102300862-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160319238-A1 | DNA-CELL CONJUGATES | ENERGY, UNITED STATES DEPARTMENT OF | 2016-11-03 | — | — | US | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
| US-9475798-B2 | Azetidine estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016150403-A1 | METHOD OF DIAGNOSIS OR TREATMENT OF NEUROLOGICAL DISORDERS WITH P75ECD AND/OR P75 | FUJIAN TIANTAI MEDICAL TECHNOLOGY CO. LTD (CN) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016142702-A1 | METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES | THERAGNOSTICS LIMITED (GB) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264944-A1 | Modified Luciferases And Uses Thereof | TARGETING SYSTEMS | 2016-09-15 | — | — | US | disclosed |
| US-20160264617-A1 | Integrated Approach to the Isolation and Purification of Antibodies | ABBOTT LABORATORIES | 2016-09-15 | — | — | US | disclosed |
| CN-102884057-B | Androgen receptor modulators and uses thereof | 亚拉冈制药公司 | 2016-09-14 | — | — | CN | disclosed |
| US-9399646-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9388414-B2 | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388413-B2 | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2809647-B1 | MGLU 2/3 AGONISTS | LILLY CO ELI (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9365557-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2016084097-A1 | PROCESS FOR PRODUCING FIBRINOGEN AND THROMBIN | HEMARUS THERAPEUTICS LTD. (IN) | 2016-06-02 | — | — | WO | disclosed |
| US-9353401-B2 | Multiplex assays with multiple luciferases reporters and uses thereof | TARGETING SYSTEMS (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2721012-B1 | BICYCLO(3.1.0)HEXANE-2,6-DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | LILLY CO ELI (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160137719-A1 | PROCESS FOR PRODUCING HIGH PURITY FIBRINOGEN AND THROMBIN FOR FIBRIN SEALANT | ICHOR BIOLOGICS PRIVATE LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| US-20160123919-A1 | OPIOID DETECTION BASED ON HIGH QUALITY GRAPHENE TRANSISTOR ARRAYS AND A SYNTHETIC MU RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-05-05 | — | — | US | disclosed |
| US-9327036-B2 | DNA-cell conjugates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102130-A1 | WATER SOLUBLE G-PROTEIN COUPLED RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-14 | — | — | US | disclosed |
| CN-105461736-A | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC | 2016-04-06 | — | — | CN | disclosed |
| US-20160090377-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090378-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9296710-B2 | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist | ELI LILLY AND COMPANY (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2989440-A2 | OPIOID DETECTION BASED ON HIGH QUALITY GRAPHENE TRANSISTOR ARRAYS AND A SYNTHETIC MU RECEPTOR | The Trustees Of The University Of Pennsylvania (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2970130-A1 | POLYCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160008323-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160002138-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | PTC THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2015184105-A1 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-03 | — | — | WO | disclosed |
| US-9193714-B2 | Fluorinated estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9187460-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9162957-B2 | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols | EDISON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150258099-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | GENENTECH, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136017-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-17 | — | — | WO | disclosed |
| US-20150252426-A1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | ARAGON PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| CN-103464108-B | A kind of golden palladium bimetallic satellite structure assembly and its preparation method and application | STATE NANOMETER SCIENCE CENTER (CN) | 2015-07-29 | — | — | CN | disclosed |
| US-9078871-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9081009-B2 | Oxidized cardiolipin and uses to detect cardiolipin antibodies | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-9051204-B2 | Nontoxic polysiloxane material for producing biologically resorbable and/or bioactive articles containing polysiloxane material, its production and use | BAYER INNOVATION GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2877599-A1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | Aragon Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-0925369-B2 | UNIVERSAL TEST SYSTEMS AND METHODS OF USE THEREOF FOR IDENTIFYING MULTIPLE FAMILIES OF MICROORGANISMS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2271936-B1 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN | VALNEVA (FR) | 2015-05-06 | — | — | EP | disclosed |
| CN-104533251-A | Polyurethane embossment fireproof door and production process thereof | ZHOU DONGPING | 2015-04-22 | — | — | CN | disclosed |
| US-20150105403-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| CN-104515760-A | Double-color fluorescence positioning super-resolution biological microscopy method and system | NANOBIOIMAGING LTD | 2015-04-15 | — | — | CN | disclosed |
| US-20150079161-A1 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150056627-A1 | APTAMERS | THE UNIVERSITY OF CHESTER (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-8956880-B2 | Detection of micro-organisms | MICAP PLC (GB) | 2015-02-17 | — | — | US | disclosed |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | ATTENUA, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150031016-A1 | Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes and Enteric Viruses | DIAGNOSTIC HYBRIDS INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2828243-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8937064-B2 | Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-1948193-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140364450-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-12-11 | — | — | US | disclosed |
| US-20140364427-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| EP-2809647-A1 | MGLU 2/3 AGONISTS | Eli Lilly and Company (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8906603-B2 | Modified cardiolipin and uses therefor | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014176544-A1 | WATER SOLUBLE G-PROTEIN COUPLED RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176524-A2 | OPIOID DETECTION BASED ON HIGH QUALITY GRAPHENE TRANSISTOR ARRAYS AND A SYNTHETIC MU RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20140322800-A1 | OXIDIZED CARDIOLIPIN AND USES TO DETECT CARDIOLIPIN ANTIBODIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2014-10-30 | — | — | US | disclosed |
| US-20140315877-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2791133-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791132-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8865751-B2 | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140308340-A1 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303137-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853382-B2 | Expression of antibody or a fragment thereof in lactobacillus | HERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853423-B2 | Indane estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| CN-102695701-B | MGLU2 agonists | ELI LILLY AND CO. (US) | 2014-10-01 | — | — | CN | disclosed |
| US-8846715-B2 | (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140288185-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE MODULATORS | TARGACEPT, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288169-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014151899-A1 | POLYCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2152696-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140256703-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-11 | — | — | US | disclosed |
| EP-2773609-A2 | NICOTINIC RECEPTOR NON-COMPETITIVE MODULATORS | Targacept, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2773759-A1 | APTAMERS | DuPont Nutrition Biosciences ApS (DK) | 2014-09-10 | — | — | EP | disclosed |
| US-8828673-B2 | Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses | DIAGNOSTIC HYBRIDS INC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140249332-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | PTC THERAPEUTICS, INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140221414-A1 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LIMITED (IN) | 2014-08-07 | — | — | US | disclosed |
| EP-2758395-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | Vertex Pharmaceuticals Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8785444-B2 | Thiazoles and pyrazoles useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778619-B2 | Oxidized cardiolipin and uses to detect cardiolipin antibodies | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-10 | — | — | US | disclosed |
| EP-2751101-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140187781-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | disclosed |
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8759389-B1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140173771-A1 | TRANSCRIPTION FACTOR MODULATING TERPENE BIOSYNTHESIS | Stichting Techno. Topinstituut Groene Genetica (Foundation Techno. top Institute Green Genetics) | 2014-06-19 | — | — | US | disclosed |
| US-8741932-B2 | Imidazopyridine derivatives | Piramal Enterprises Limited (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2734512-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | Edison Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8735593-B2 | Aminopyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140141099-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-22 | — | — | US | disclosed |
| US-20140113944-A1 | BICYCLO (3.1.0) HEXANE-2, 6-DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2721012-A1 | BICYCLO (3.1.0) HEXANE- 2, 6 -DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | Eli Lilly and Company (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2718309-A1 | TRANSCRIPTION FACTOR MODULATING TERPENE BIOSYNTHESIS | Stichting Technologisch Topinstituut Groene Genetica (Foundation Technological Top Institute Green Genetics) (NL) | 2014-04-16 | — | — | EP | disclosed |
| US-20140087398-A1 | OXIDIZED CARDIOLIPIN AND USES TO DETECT CARDIOLIPIN ANTIBODIES | Arlington Scientific, Inc. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8664219-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| CN-103596933-A | Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as MGLU2 receptor agonist | LILLY CO ELI | 2014-02-19 | — | — | CN | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140037754-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014018926-A1 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY | ARAGON PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20140024673-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT,INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140018352-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2014004417-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| CN-103464108-A | Gold-palladium thermometal satellite structure assembly as well as preparation method and application thereof | NAT CT NANOSCIENCE NCNST CHINA | 2013-12-25 | — | — | CN | disclosed |
| US-20130323819-A1 | EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS | HERA PHARMACEUTICALS, INC. | 2013-12-05 | — | — | US | disclosed |
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-05 | — | — | US | disclosed |
| US-8598361-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130310433-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-21 | — | — | US | disclosed |
| WO-2013171281-A1 | HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS | VIVALIS (FR) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310428-A1 | THERMO-STABLE, ARSENIC-FREE SYNERGISTIC BIOCIDE CONCENTRATE COMPOSITION FOR POLYMER MATRICES AND PROCESS FOR PREPARING SAME | ISP INVESTMENTS INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2190849-B1 | 4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2664616-A1 | Hydantoin and thiohydantoin derivatives as antiviral drugs | Vivalis (FR) | 2013-11-20 | — | — | EP | disclosed |
| EP-2661421-A2 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | Targacept, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8575214-B2 | MGlu 2/3 agonists | ELI LILLY AND COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130281445-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8557818-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557833-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-10 | — | — | US | disclosed |
| US-20130261114-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-03 | — | — | US | disclosed |
| WO-2013142266-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| EP-1949108-B1 | MODIFIED CARDIOLIPIN AND USES THEREFOR | US GOV HEALTH & HUMAN SERV (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8541446-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245273-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2516406-B1 | MGLU2 AGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130236496-A1 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE | UNIVERSITE DE LAVAL (CA) | 2013-09-12 | — | — | US | disclosed |
| EP-2134707-B1 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1951715-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8524902-B2 | [1,2,4]triazolo[4,3-f]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8518953-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2013116174-A1 | MGLU 2/3 AGONISTS | ELI LILLY AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130197079-A1 | MGLU 2/3 AGONISTS | ELI LILY AND COMPANY (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| CN-101420955-B | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMA | 2013-07-17 | — | — | CN | disclosed |
| US-8481578-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013090836-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090829-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| CN-202994798-U | Diagnostic kit for diagnosis of rheumatoid arthritis | SHANGHAI KEXIN BIOTECH CO LTD | 2013-06-12 | — | — | CN | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8455534-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013067105-A2 | NICOTINIC RECEPTOR NON-COMPETITIVE MODULATORS | TARGACEPT, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064818-A1 | APTAMERS | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116228-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
| CN-101360997-B | Modified cardiolipin and uses therefor | US GOVERNMENT (US) | 2013-05-01 | — | — | CN | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130096302-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-04-18 | — | — | US | disclosed |
| EP-2580210-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130090479-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2576496-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | Targacept, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410133-B2 | Aminopyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| WO-2013043961-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043960-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-28 | — | — | WO | disclosed |
| US-8399478-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8383633-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-26 | — | — | US | disclosed |
| US-8372835-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372850-B2 | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2013013078-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | EDISON PHARMECEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2545025-A1 | SYNTHESIS OF ALPHA-TOCOPHEROLQUINONE DERIVATIVES, AND METHODS OF USING THE SAME | Edison Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2182949-B1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2536708-A2 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012173850-A1 | BICYCLO (3.1.0) HEXANE- 2, 6 -DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2176261-B1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMA (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012169893-A1 | TRANSCRIPTION FACTOR MODULATING TERPENE BIOSYNTHESIS | STICHTING TECHNOLOGISCH TOPINSTITUUT GROENE GENETICA (FOUNDATION TECHNOLOGICAL TOP INSTITUTE GREEN GENETICS) (NL) | 2012-12-13 | — | — | WO | disclosed |
| US-8318184-B2 | MGLU2 agonists | ELI LILLY AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2516406-A1 | MGLU2 AGONISTS | Eli Lilly and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2007757-B1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-10-03 | — | — | EP | disclosed |
| CN-102695701-A | MGLU2 agonists | LILLY CO ELI | 2012-09-26 | — | — | CN | disclosed |
| WO-2012125735-A1 | AN INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES | ABOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238730-A1 | INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | US | disclosed |
| US-8268811-B2 | Thiazoles and pyrazoles useful as kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232072-A1 | IMIDAZOPYRIDINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-09-13 | — | — | US | disclosed |
| EP-2496577-A1 | IMIDAZOPYRIDINE DERIVATIVES | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| EP-2493456-A2 | SOLID DISPERSION OF RIFAXIMIN | Lupin Limited (IN) | 2012-09-05 | — | — | EP | disclosed |
| EP-2019826-B1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120214833-A1 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-8247393-B2 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242272-B2 | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8236832-B2 | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120196276-A1 | Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes and Enteric Viruses | QUIDEL CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120189579-A1 | SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-07-26 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012093174-A1 | 1-(6-MEMBERED AZO-HETEROCYCLIC)-2,5-DIHYDRO-1H-PYRROL-2-ONE DERIVATIVES AS ANTI-HEPATITIS C VIRUS, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012094437-A2 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| EP-2474546-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | Vertex Pharmaceuticals Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8217024-B2 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120165378-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2467364-A2 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-8206675-B2 | Nontoxic polyethoxysiloxane material or the production of biologically resorbable and/or bioactive articles containing polyethoxysiloxane material, the production thereof, and the use thereof | BAYER INNOVATION GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120156705-A1 | LUCIFERASES AND USES THEREOF | TARGETING SYSTEMS (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2465501-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of preparation | Targacept Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120149898-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1989205-B1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142088-A1 | DNA-CELL CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
| US-8188134-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129885-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2451453-A1 | SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012019058-A9 | EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS | HERA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-8142997-B2 | Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses | Diagnostic Hybrids, Inc—Quidel Corporation (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2431037-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | Targacept, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1919891-B1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8129387-B2 | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129399-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8119659-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2418210-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2417249-A1 | DNA-CELL CONJUGATES | The Regents of the University of California (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012019054-A2 | EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS | HERA PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012019058-A1 | EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS | HERA PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2012000082-A1 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-L-LIKE RECEPTOR LIGAND OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE | UNIVERSITé LAVAL (CA) | 2012-01-05 | — | — | WO | disclosed |
| US-20110315625-A1 | DETECTION OF MICRO-ORGANISMS | MILLIPORE CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011159769-A2 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011149859-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | TARGACEPT, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149862-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS MODULATORS | TARGACEPT, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-102264721-A | Compounds useful as inhibitors of ATR kinase | — | 2011-11-30 | — | — | CN | disclosed |
| US-8067417-B2 | Imidazo[1,2-F]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110288095-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2007732-B1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110263720-A1 | SYNTHESIS OF ALPHA-TOCOPHEROLQUINONE DERIVATIVES, AND METHODS OF USING THE SAME | PENWEST PHARMACEUTICALS CO. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263859-A1 | (2S, 3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| EP-2376485-A1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-10-19 | — | — | EP | disclosed |
| US-8039206-B1 | Detection of micro-organisms | MILLIPORE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039661-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110251085-A1 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN | VIVALIS (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-2094712-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1919906-B1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2370424-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2137183-B1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2011-09-28 | — | — | EP | disclosed |
| US-8022202-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2011112679-A1 | SYNTHESIS OF ALPHA-TOCOPHEROLQUINONE DERIVATIVES, AND METHODS OF USING THE SAME | PENWEST PHARMACEUTICALS CO. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110223659-A1 | Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus | DIAGNOSTIC HYBRIDS, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-15 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011103202-A2 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110190507-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110178146-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7981906-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| WO-2011084437-A1 | MGLU2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110152334-A1 | MGLU2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110136143-A1 | MODIFIED CARDIOLIPIN AND USES THEREFOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2011-06-09 | — | — | US | disclosed |
| EP-2325184-A1 | Azaindoles useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055320-A1 | IMIDAZOPYRIDINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011051971-A2 | SOLID DISPERSION OF RIFAXIMIN | LUPIN LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
| EP-2316835-A1 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1951716-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110081364-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2011-04-07 | — | — | US | disclosed |
| US-7915305-B2 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2295413-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295412-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2011025980-A1 | MODIFIED LUCIFERASES AND USES THEREOF | TARGETING SYSTEMS (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-2289486-A1 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | Teva Women's Health, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289487-A1 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | Teva Women's Health, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046104-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-24 | — | — | US | disclosed |
| US-7888043-B2 | Modified cardiolipin and uses therefor | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2102210-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110020377-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021559-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020469-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20110009023-A1 | NONTOXIC POLYSILOXANE MATERIAL FOR PRODUCING BIOLOGICALLY RESORBABLE AND/OR BIOACTIVE ARTICLES CONTAINING POLYSILOXANE MATERIAL, ITS PRODUCTION AND USE | BAYER INNOVATION GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| WO-2011004018-A1 | SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2271936-A1 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN | Vivalis (FR) | 2011-01-12 | — | — | EP | disclosed |
| EP-2262498-A2 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmceuticals Incorporated (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100317641-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-7851495-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7846655-B2 | Compositions and methods for detecting a non plus-stranded RNA virus | DIAGNOSTIC HYBRIDS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2252618-A1 | PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2249430-A1 | COMPOSITE MATERIAL, PHOTOELECTRIC CONVERSION MATERIAL, DYE-SENSITIZED SOLAR CELL, DYE-SENSITIZED SOLAR CELL DEVICE, MANUFACTURING METHOD FOR PHOTOELECTRIC CONVERSION DEVICE, AND METHOD OF ANALYZING OXYGEN TITANIUM CRYSTAL STRUCTURE | The University of Tokyo (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-7829590-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2010-11-09 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7820685-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100266690-A1 | STABILIZER CONCENTRATE FOR MATRIX COMPOSITIONS PROCESSED AT ELEVATED TEMPERATURES | TROY TECHNOLOGY II, INC. | 2010-10-21 | — | — | US | disclosed |
| US-7816490-B2 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | IMMUNE DISEASE INSTITUTE, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010118235-A1 | DNA-CELL CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-1812440-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7795259-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1983987-B1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7786130-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786283-B2 | BRI constructs and methods of using | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100215772-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | US | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| CN-101801959-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2010-08-11 | — | — | CN | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-22 | — | — | US | disclosed |
| EP-2099787-B1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-07-21 | — | — | EP | disclosed |
| CN-101784273-A | (2S,3R) -N- (2- ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT INC | 2010-07-21 | — | — | CN | disclosed |
| US-20100173280-A1 | Systems for Detection and Production of Respiratory, Herpes and Enteric Viruses | DIAGNOSTIC HYBRIDS, INC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100174045-A1 | NONTOXIC POLYETHOXYSILOXANE MATERIAL OR THE PRODUCTION OF BIOLOGICALLY RESORBABLE AND OR BIOACTIVE ARTICLES CONTAINING POLYETHOXYSILOXANE MATERIAL, THE PRODUCTION THEREOF, AND THE USE THEREOF | JIANGSU SYNECOUN MEDICAL TECHNOLOGY CO., LTD. (CN) | 2010-07-08 | — | — | US | disclosed |
| EP-2203054-A1 | STABILIZER CONCENTRATE FOR MATRIX COMPOSITIONS PROCESSED AT ELEVATED TEMPERATURES | Isp Investments Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2010071837-A1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2190849-A2 | COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009145814-A9 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054398-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2182949-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | Targacept Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-22 | — | — | US | disclosed |
| EP-2176261-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2010-04-21 | — | — | EP | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| US-7691885-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101687852-A | Thiazoles and pyrazoles useful as kinase inhibitors | VERTEX PHARMA | 2010-03-31 | — | — | CN | disclosed |
| EP-2164842-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| CN-101679378-A | Thiazoles and pyrazoles as kinase inhibitors | VERTEX PHARMA | 2010-03-24 | — | — | CN | disclosed |
| CN-101679387-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2010-03-24 | — | — | CN | disclosed |
| CN-101679386-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2010-03-24 | — | — | CN | disclosed |
| CN-101675041-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2010-03-17 | — | — | CN | disclosed |
| EP-1451366-B1 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | RIBOMED BIOTECHNOLOGIES INC (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-2155730-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100037713-A1 | Pharmaceutical Analysis Apparatus and Method | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| EP-2152696-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2152694-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2086965-B1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7659283-B2 | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| EP-2148931-A2 | DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20100022502-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2146982-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2137183-A2 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2134707-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134709-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2131816-A1 | PHARMACEUTICAL ANALYSIS APPARATUS AND METHOD | Smithkline Beecham Corporation (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-10 | — | — | US | disclosed |
| EP-1692140-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009145814-A2 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090286840-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-19 | — | — | US | disclosed |
| US-20090286222-A1 | Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes And Enteric Viruses | QUIDEL CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-2102210-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7592169-B2 | Methods and compositions for treatment and prevention of HSV-2 infections and conditions | MEDIMMUNE, LLC (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009112592-A1 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN | VIVALIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| EP-2099787-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2101173-A1 | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein | Vivalis (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-7589214-B2 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2094712-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1798556-B1 | Device for the early and rapid immunochromatographic detection of HIV and uses thereof | JORDANIAN PHARMACEUTICAL MFG (JO) | 2009-08-26 | — | — | EP | disclosed |
| EP-2086965-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090186422-A1 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES | THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC., A MASSACHUSETTS CORPORATION | 2009-07-23 | — | — | US | disclosed |
| US-20090181938-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009085913-A1 | PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-2076122-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| CN-101466380-A | Methods and compositions for the treatment of parkinson's disease | MCLEAN HOSPITAL CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| US-7541165-B2 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-7528142-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528138-B2 | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-05 | — | — | US | disclosed |
| CN-101420955-A | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-04-29 | — | — | CN | disclosed |
| WO-2009046172-A1 | STABILIZER CONCENTRATE FOR MATRIX COMPOSITIONS PROCESSED AT ELEVATED TEMPERATURES | ISP INVESTMENTS INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| EP-2027116-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1107665-B1 | METHOD OF DIAGNOSIS OF PROSTATE CANCER | UROPATH PTY LTD (AU) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TRAMES BIO, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2009018415-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3, 4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018505-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-2019826-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101360997-A | Modified cardiolipin and uses therefor | US GOV HEALTH & HUMAN SERV (US) | 2009-02-04 | — | — | CN | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-2010542-A2 | 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7473775-B2 | Abortive promoter cassettes | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-2007757-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007732-A2 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470511-B2 | Methods for determining nucleic acid methylation | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-2004645-A2 | PYRROLO(3,2-C) PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468261-B2 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080311597-A1 | Modified Cardiolipin and Uses Therefor | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION | 2008-12-18 | — | — | US | disclosed |
| WO-2008147626-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008137619-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137621-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137622-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1989205-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008131103-A2 | DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1983987-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7442508-B2 | Mixture of biological cells, used for detection and medical diagnosis of viruses; microbiology; Detecting and differentiating viruses or intracellular parasites present in a specimen; inoculating culture with pathogen and observing for its presence | DIAGNOSTIC HYBRIDS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008128009-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7435588-B2 | Systems for detection and production of respiratory, herpes and enteric viruses | DIAGNOSTIC HYBRIDS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1971325-A2 | CONJUGATED ESTROGEN COMPOSITIONS, APPLICATORS, KITS, AND METHODS OF MAKING AND USE THEREOF | Duramed Pharmaceuticals, Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008112642-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112651-A2 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112646-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008109723-A1 | PHARMACEUTICAL ANALYSIS APPARATUS AND METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1954277-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951716-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951715-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948193-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1949108-A2 | MODIFIED CARDIOLIPIN AND USES THEREFOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008089405-A1 | COMPOSITION OF MULTIPLE HORMONES DELIVERED VAGINALLY IN A SINGLE CREAM | NEUROSCI, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1945811-A2 | SYSTEMS FOR DETECTION AND PRODUCTION OF RESPIRATORY, HERPES AND ENTERIC VIRUSES | Diagnostic Hybrids (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2008077086-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076392-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008057940-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1919906-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1919891-A1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080108546-A1 | Novel Human Card-Only Protein That Inhibits Pro-Il-1 Beta Maturation | VLAAMS INTERUNIVERSITAIR INSTITUUT (BE) | 2008-05-08 | — | — | US | disclosed |
| US-20080076115-A1 | Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus | DIAGNOSTIC HYBRIDGS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080070965-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-03-20 | — | — | US | disclosed |
| US-20080070882-A1 | Vaginal cream compositions, kits thereof and methods of using thereof | TEVA WOMEN'S HEALTH, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080051377-A1 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | DURAMED PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080032963-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
| WO-2007139816-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139795-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1622923-A4 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | RIBOMED BIOTECHNOLOGIES INC (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1109552-A4 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RES DEV FOUNDATION (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007120760-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007117692-A2 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| CN-101037438-A | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-09-19 | — | — | CN | disclosed |
| US-20070213327-A1 | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| EP-1831168-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | Vertex Pharmaceuticals Incorporated (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095223-A2 | PYRROLO(3,2-C) PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191321-A1 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1814882-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007087283-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1812440-A1 | PYRAZOLOÝ1,5-a¨PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070155794-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| WO-2007076144-A2 | CONJUGATED ESTROGEN COMPOSITIONS, APPLICATORS, KITS, AND METHODS OF MAKING AND USE THEREOF | DURAMED PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1360274-B1 | DETECTION OF MICRO-ORGANISMS | MILLIPORE CORP (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1485376-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068310-A1 | DEVICE FOR THE EARLY AND RAPID IMMUNOCHROMATOGRAPHIC DETECTION OF HIV AND USES THEREOF | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2007-06-21 | — | — | WO | disclosed |
| EP-1798556-A1 | Device for the early and rapid immunochromatographic detection of HIV and uses thereof | The Jordanian Pharmaceutical Manufacturing Co. (JO) | 2007-06-20 | — | — | EP | disclosed |
| CN-1319968-C | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-06-06 | — | — | CN | disclosed |
| US-7226738-B2 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2007061793-A2 | MODIFIED CARDIOLIPIN AND USES THEREFOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SCIENCES, CENTERS FOR DISEASE CONTROL AND PREVENTION (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059299-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007056164-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056163-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1147188-B1 | INTERNAL RIBOSOME ENTRY SITE (IRES), VECTOR CONTAINING SAME AND THE USES THEREOF | VLAAMS INTERUNIV INST BIOTECH (BE) | 2007-05-16 | — | — | EP | disclosed |
| EP-1784192-A2 | VAGINAL CREAM COMPOSITIONS, KITS THEREOF AND METHODS OF USING THEREOF | Duramed Pharmaceuticals, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099296-A1 | Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs | MONOGRAM BIOSCIENCES, INC. | 2007-05-03 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007035856-A2 | SYSTEMS FOR DETECTION AND PRODUCTION OF RESPIRATORY, HERPES AND ENTERIC VIRUSES | DIAGNOSTIC HYBRIDS (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1765819-A1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070065939-A1 | Systems for detection and production of respiratory, herpes and enteric viruses | UNIVERSITY HOSPITALS OF CLEVELAND (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027594-A1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070048774-A1 | Continuous in-vitro evolution | DIATECH PTY LTD. | 2007-03-01 | — | — | US | disclosed |
| US-20070042403-A1 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | CENTER FOR BLOOD RESEARCH, INC. | 2007-02-22 | — | — | US | disclosed |
| EP-1751182-A1 | A NOVEL HUMAN CARD-ONLY PROTEIN THAT INHIBITS PRO-IL-1 BETA; MATURATION | VIB vzw (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1739087-A1 | Pyrazole compositions useful as inhibitors of gsk-3 | Vertex Pharmaceuticals Incorporated (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060286667-A1 | Mixture of biological cells, used for detection and medical diagnosis of viruses; microbiology; Detecting and differentiating viruses or intracellular parasites present in a specimen; inoculating culture with pathogen and observing for its presence | DIAGNOSTIC HYBRIDS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060258662-A1 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-16 | — | — | US | disclosed |
| EP-1716151-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7129042-B2 | detecting the presence SARS-coronavirus sgRNA in a sample; | DIAGNOSTIC HYBRIDS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060236435-A1 | Chimeric plant promoters and plants containing the same | MERISTEM THERAPEUTICS | 2006-10-19 | — | — | US | disclosed |
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060204964-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | HANNA MICHELLE M | 2006-09-14 | — | — | US | disclosed |
| EP-1451366-A4 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | RIBOMED BIOTECHNOLOGIES INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1532145-B1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060188942-A1 | Detection of Micro-Organisms | MICAP PLC (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1692140-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-17 | — | — | US | disclosed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060177640-A1 | Laminated film and method for producing same | TORAY INDUSTRIES, INC. (JP) | 2006-08-10 | — | — | US | disclosed |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| CN-1812973-A | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICAL CO LTD (US) | 2006-08-02 | — | — | CN | disclosed |
| US-7084241-B2 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060166936-A1 | Diaminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| EP-1220935-B1 | SYNTHETIC AND CHIMERIC PROMOTERS, EXPRESSION CASSETTES, PLASMIDS, VECTORS, TRANSGENIC PLANTS AND SEEDS CONTAINING THEM, AND METHOD FOR PRODUCING THEM | MERISTEM THERAPEUTICS (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006065946-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135537-A1 | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-22 | — | — | US | disclosed |
| US-20060122213-A1 | Azaindoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| WO-2006058074-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1660487-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006052913-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-18 | — | — | WO | disclosed |
| US-7045319-B2 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| WO-2006050249-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-11 | — | — | WO | disclosed |
| US-7041687-B2 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060094105-A1 | Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses | UNIVERSITY HOSPITALS OF CLEVELAND (US) | 2006-05-04 | — | — | US | disclosed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-7019008-B2 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| WO-2006023496-A2 | VAGINAL CREAM COMPOSITIONS, KITS THEREOF AND METHODS OF USING THEREOF | DURAMED PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| CN-1243545-C | DNA-cleaving antitumor agents | RES DEV FOUNDATION (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20060040904-A1 | Vaginal cream compositions, kits thereof and methods of using thereof | DURAMED PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1622923-A2 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | Ribomed Biotechnologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010084-A2 | A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2006-01-26 | — | — | WO | disclosed |
| US-20060008895-A1 | Microarray chip for detection of immunoglobulin | CHENG LOONG CORPORATION (TW) | 2006-01-12 | — | — | US | disclosed |
| WO-2006004984-A1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-1351688-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1385495-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1165815-B1 | CHIMERIC EXPRESSION PROMOTERS ORIGINATING FROM COMMELINA YELLOW MOTTLE VIRUS AND CASSAVA VEIN MOSAIC VIRUS | MERISTEM THERAPEUTICS (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005118632-A1 | A NOVEL HUMAN CARD-ONLY PROTEIN THAT INHIBITS PRO-IL-1β MATURATION | VIB VZW (BE) | 2005-12-15 | — | — | WO | disclosed |
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1385840-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-6963021-B2 | Chimeric expression promoters originating from commelina yellow mottle virus and cassava vein mosaic virus | MERISTEM THERAPEUTICS (FR) | 2005-11-08 | — | — | US | disclosed |
| WO-2005094324-A2 | MIXED CELL DIAGNOSTIC SYSTEMS | DIAGNOSTIC HYBRIDS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095406-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1681815-A | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1582340-A1 | LAMINATED FILM AND METHOD FOR PRODUCING SAME | TORAY INDUSTRIES, INC. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
| EP-0804565-B1 | TETRACYCLINE-REGULATED TRANSCRIPTIONAL MODULATORS | TET SYSTEMS HOLDING GMBH & CO (DE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575365-A1 | ACTIVE INSECTICIDE MATERIAL, PREPARATION METHOD AND USES THEREOF | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2005-09-21 | — | — | EP | disclosed |
| US-6946291-B2 | Mixed cell diagnostic systems | UNIVERSITY HOSPITALS OF CLEVELAND (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | SMITHKLINE BEECHAM CORPORATION | 2005-09-08 | — | — | US | disclosed |
| EP-1385830-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6919470-B2 | Aryl and heteroaryl sulfonates | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| US-6914124-B2 | Tetracycline-regulated transcriptional activator fusion proteins | TET SYSTEMS HOLDING GMBH & CO. KG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-6908948-B1 | DNA-cleaving antitumor agents | RESEARCH DEVELOPMENT FOUNDATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050112142-A1 | Methods and compositions for treatment and prevention of HSV-2 infections and conditions | MEDIMMUNE, LLC | 2005-05-26 | — | — | US | disclosed |
| EP-1532145-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005042767-A2 | COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | DIAGNOSTIC HYBRIDS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | VERTEX PHARMACEUTICALS INCORPORATED | 2005-05-12 | — | — | US | disclosed |
| US-20050095582-A1 | Compositions and methods for detecting severe acute respiratory syndrome coronavirus | DIAGNOSTIC HYBRIDS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005037843-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050064414-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1381365-A4 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-0722492-B1 | STABILISATION OF PROTEINS IN SOLUTION | UNIV LEEDS INNOVATIONS LTD (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1385841-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2005016920-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050026150-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-6846928-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1485376-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040234996-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| WO-2004096997-A2 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040214886-A1 | Phenoxyphenyl alkanesulphonates | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1467972-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1246619-B1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040198979-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040175724-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | DESIGNER GENES, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040170965-A1 | Mixed cell diagnostic systems | QUIDEL CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1451366-A2 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | Ribomed Biotechnologies, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6783756-B2 | INTRODUCING INTO THE CELL A NUCLEIC ACID MOLECULE ENCODING A TETRACYCLINE-CONTROLLABLE TRANSACTIVATOR (TTA) COMPRISING TET REPRESSOR OPERABLY LINKED TO A POLYPEPTIDE WHICH OR ACTIVATES TRANSCRIPTION IN EUCARYOTIC CELL; MODULATING | ABBOTT GMBH & CO., KG (DE) | 2004-08-31 | — | — | US | disclosed |
| WO-2004069200-A2 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES | THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157257-A1 | Abortive promoter cassettes | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-0642666-B2 | HEPATITIS C ASSAY | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1387679-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152895-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004064525-A1 | ACTIVE INSECTICIDE MATERIAL, PREPARATION METHOD AND USES THEREOF | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2004-08-05 | — | — | WO | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20040142948-A1 | Sulfonamides | DHANAK DASHYANT (US) | 2004-07-22 | — | — | US | disclosed |
| US-20040142923-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | disclosed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6764852-B2 | NUCLEOTIDE SEQUENCE ENABLING A CELL CYCLE DEPENDENT INITIATION OF TRANSLATION OF MRNA. | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2004-07-20 | — | — | US | disclosed |
| US-20040137461-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | DESIGNER GENES, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-20040131701-A1 | Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs | VIROCELL INC. | 2004-07-08 | — | — | US | disclosed |
| US-6756409-B2 | FOR THERAPY AND PROPHYLAXIS OF PAIN AND/OR NEURODEGENERATIVE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-29 | — | — | US | disclosed |
| EP-1233774-A4 | UROTENSIN-II ANALOGS | SMITHKLINE BEECHAM CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004043368-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043948-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043366-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043463-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043369-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040096821-A1 | Detection of micro-organisms | EMD MILLIPORE CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040082566-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040054162-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040053963-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1198554-B1 | DETECTION OF MICRO-ORGANISMS | MICAP PLC (GB) | 2004-03-10 | — | — | EP | disclosed |
| US-6703211-B1 | CELLULAR DETECTION EVEN IN A LARGE BACKGROUND OF ADENOSINE TRIPHOSPHATE (ATP) IN THE SAMPLE, USES ENDOGENOUS ENZYMES TO CONVERT ADENOSINE MONOPHOSPHATE (AMP) TO ATP AND DCTP; FOOD AND WATER SAFETY | PROMEGA CORPORATION | 2004-03-09 | — | — | US | disclosed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| WO-2004013140-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1387679-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-1385840-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385841-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385830-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385495-A2 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686345-B2 | INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| US-20040018606-A1 | Control of protein systemic delivery by hypoxia using a tet-HIF1-alpha chimeric transactivator | BOHL DELPHINE (FR) | 2004-01-29 | — | — | US | disclosed |
| EP-1381365-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1351687-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| EP-1379237-A2 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379519-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379503-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677157-B1 | SIGNIFICANT REDUCTION OR ABSENCE OF PROSTATE SECRETORY GRANULES, EOSINOPHILIC BODIES, DECAPITATED CYTOPLASMIC BODIES AND/OR CORPORA AMYLACEA INDICATIVE OF ADENOCARCINOMA | UROPATH PTY LTD., A.C.N. (AU) | 2004-01-13 | — | — | US | disclosed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040002117-A1 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | CBR INSTITUTE OF BIOMEDICAL RESEARCH, INC., THE | 2004-01-01 | — | — | US | disclosed |
| US-20040003417-A1 | ANIMALS TRANSGENIC FOR A TETRACYCLINE-REGULATED TRANSCRIPTIONAL INHIBITOR | TET SYSTEMS HOLDING GMBH & CO. KG (DE) | 2004-01-01 | — | — | US | disclosed |
| US-20030232802-A1 | Aryl and heteroaryl sulfonates | HEIL MARKUS (DE) | 2003-12-18 | — | — | US | disclosed |
| US-20030225073-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-20030221204-A1 | BRI constructs and methods of using | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2003-11-27 | — | — | US | disclosed |
| WO-2003093492-A2 | COMPOSITIONS AND METHODS FOR DETERMINING SUSCEPTIBILITY OF HEPATITIS C VIRUS TO ANTI-VIRAL DRUGS | VIROLOGIC, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1360274-A1 | DETECTION OF MICRO-ORGANISMS | Fluid Technologies Plc (GB) | 2003-11-12 | — | — | EP | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030203356-A1 | RNase L activator-antisense complexes | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6627735-B2 | Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of diabetes | ZYMOGENETICS, INC. | 2003-09-30 | — | — | US | disclosed |
| WO-2003078423-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1343507-A2 | METHOD TO TREAT INFECTIOUS DISEASES AND/OR TO ENHANCE ANTIMICROBIAL EFFICACY OF DRUGS | Virocell Inc. (CA) | 2003-09-17 | — | — | EP | disclosed |
| EP-1244452-B1 | CARBOXAMIDE DERIVATES OF PYRROLIDINE AND PIPERIDINE AS UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030170820-A1 | Continuous in- vitro evolution | DIATECH PTY LTD. (AU) | 2003-09-11 | — | — | US | disclosed |
| US-20030166067-A1 | Comprises nucleotide sequences coding pancreatic polypeptide comprising tyrosine phosphatase activity for use in diagnosing, preventing and treating diabetes and autoimmune disorders; immunoassay; drug screening | ZYMOGENETICS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6605639-B1 | Treating and/or preventing diseases alleviated by retinoid X receptor ligand dependent transcriptional regulation using ascochlorin or derivatives | NUCLEAR RECEPTOR RESEARCH, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| WO-2003064397-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003062258-A1 | RNASE L ACTIVATOR-ANTISENSE COMPLEXES | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030138774-A1 | Methods and apparatus for separating and detecting nucleic acid | EXACT SCIENCES CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-6596476-B1 | Kit for use in detection of viral diseases | ABBOTT LABORATORIES | 2003-07-22 | — | — | US | disclosed |
| US-6593083-B1 | For the detection of antibodies in body fluids; contacting the sample with polypeptide or fusion protein; detecting the antibody-polypeptide complex | DEVARE SUSHIL G (US) | 2003-07-15 | — | — | US | disclosed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | disclosed |
| US-20030099950-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | RIBOMED BIOTECHNOLOGIES, INC. | 2003-05-29 | — | — | US | disclosed |
| EP-0925369-B1 | UNIVERSAL TEST SYSTEMS AND METHODS OF USE THEREOF FOR IDENTIFYING MULTIPLE FAMILIES OF MICROORGANISMS | DADE MICROSAN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003038042-A2 | MOLECULAR DETECTION SYSTEMS UTILIZING REITERATIVE OLIGONUCLEOTIDE SYNTHESIS | RIBOMED BIOTECHNOLOGIES, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1233776-A4 | UROTENSIN-II CYCLIC ANALOGS | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1246619-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6548609-B2 | Epoxidation of vegetable oils using organic acid with oxygenated water or peracetic acid to obtain epoxydized oils and/or mixtures of esters of epoxydized unsaturated acids; reacting with alcohol or amine or alcoholamine | RESINAS Y MATERIALES S.A. DE C.V. (MX) | 2003-04-15 | — | — | US | disclosed |
| US-6544992-B1 | Carbonylamino pyrrolidine and piperidine derivatives | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
| EP-1107665-A4 | METHOD OF DIAGNOSIS OF PROSTATE CANCER | UROPATH PTY LTD (AU) | 2003-04-02 | — | — | EP | disclosed |
| EP-1293575-A2 | Universal test system and methods of use thereof for indentifying multiple families of microorganisms | Dade Microsan Inc. (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1285965-A1 | Bifactorial endosperm box, trans-activating factor that binds thereto, and method of regulation of promoter activity | MERISTEM THERAPEUTICS (FR) | 2003-02-26 | — | — | EP | disclosed |
| WO-2003014349-A1 | BIFACTORIAL ENDOSPERM BOX, TRANS-ACTIVATING FACTOR THAT BINDS THERETO, AND METHOD OF REGULATION OF PROMOTER ACTIVITY | MERISTEM THERAPEUTICS SA (FR) | 2003-02-20 | — | — | WO | disclosed |
| US-20030028011-A1 | Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs | VIROLOGIC, INC. | 2003-02-06 | — | — | US | disclosed |
| US-20030028922-A1 | Chimeric expression promoters originating from commelina yellow mottle virus and cassava vein mosaic virus | MERISTEM THERAPEUTICS (FR) | 2003-02-06 | — | — | US | disclosed |
| US-6514970-B1 | Pyrrolidines such as benzo(b)thiophene-2-carboxylic acid ((S)-1-((S)-1-(4-(1-benzyl-piperidin-4-yloxy)-3-chloro-benzyl)-pyrrolidin-3 -ylcarbamoyl)-3- methyl-butyl)-amide | SMITHKLINE BEECHAM CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20030022315-A1 | Tetracycline-inducible transcriptional inhibitor fusion proteins | BASF AKTIENGESELLSCHAFT AND KNOLL AKTIENGESELLSCHAFT | 2003-01-30 | — | — | US | disclosed |
| US-20030022934-A1 | Phenoxyphenyl alkanesulphonates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| US-6511812-B1 | Adding denatured and/or purified bacterial enzyme; recombinant antigens expressed as fusion proteins with a bacterial enzyme which is CKS | ABBOTT LABORATORIES | 2003-01-28 | — | — | US | disclosed |
| EP-1244452-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001053817-A9 | METHODS OF AND APPARATUS FOR SEPARATING AND DETECTING NUCLEIC ACID | MOSAIC TECHNOLOGIES (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002754-A2 | BRI CONSTRUCTS AND METHODS OF USING | MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1105428-A4 | NOVEL CLEAVED FRAGMENTS OF FIBRINOGEN | NEW YORK BLOOD CT INC (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020168722-A1 | Novel cleaved fragments of fibrinogen | NATIONAL INSTITUTES OF HEALTH-DEITR | 2002-11-14 | — | — | US | disclosed |
| WO-2002090337-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090348-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090353-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089740-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089793-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1255983-A2 | METHODS OF AND APPARATUS FOR SEPARATING AND DETECTING NUCLEIC ACID | Mosaic Technologies (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020155443-A1 | Metal binding DNA interactive compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-24 | — | — | US | disclosed |
| US-20020152487-A1 | Transgenic organisms having tetracycline-regulated transcriptional regulatory systems | BASF AKTIENGESELLSCHAFT | 2002-10-17 | — | — | US | disclosed |
| US-20020152489-A1 | Transgenic organisms having tetracycline-regulated transcriptional regulatory systems | BASF AKTIENGESELLSCHAFT | 2002-10-17 | — | — | US | disclosed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002078641-A2 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002079155-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002078707-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002079188-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1246619-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1244452-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020132797-A1 | DNA-cleaving antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-20020132300-A1 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | CENTER FOR BLOOD RESEARCH | 2002-09-19 | — | — | US | disclosed |
| EP-1233776-A1 | UROTENSIN-II CYCLIC ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1233774-A1 | UROTENSIN-II ANALOGS | SmithKline Beecham Corporation (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002062941-A1 | DETECTION OF MICRO-ORGANISMS | MICAP PLC (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-20020102616-A1 | Islet cell antigen 1851 | ZYMOGENETICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
| EP-1220935-A1 | SYNTHETIC AND CHIMERIC PROMOTERS, EXPRESSION CASSETTES, PLASMIDS, VECTORS, TRANSGENIC PLANTS AND SEEDS CONTAINING THEM, AND METHOD FOR PRODUCING THEM | MERISTEM THERAPEUTICS (FR) | 2002-07-10 | — | — | EP | disclosed |
| US-6416963-B1 | CONTACTING FIBRINOGEN DIGEST COMPRISING ALPHAE CX FIBRINOGEN PRODUCED BY PROTEOLYTIC ENZYME DIGESTION WITH AT LEAST ONE ANTIBODY THAT SPECIFICALLY BINDS TO ALPHAE C DOMAIN OF FIBRINOGEN, SELECTIVELY REMOVING ALPHAE CX FIBRINOGEN | NEW YORK BLOOD CENTER | 2002-07-09 | — | — | US | disclosed |
| US-20020086426-A1 | Tetracycline-regulated transcriptional activator fusion proteins | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | US | disclosed |
| US-20020083486-A1 | Chimeric plant promoters and plants containing the same | MERISTEM THERAPEUTICS (FR) | 2002-06-27 | — | — | US | disclosed |
| US-20020077307-A1 | METHODS FOR REGULATING GENE EXPRESSION | TET SYSTEMS HOLDING GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
| CN-1348436-A | Novel ligands of nuclear receptors PPAR's | NUCLEAR RECEPTOR RES LTD (JP) | 2002-05-08 | — | — | CN | disclosed |
| US-20020049181-A1 | Novel internal ribosome entry site, vector containing same and uses thereof | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR (BE) | 2002-04-25 | — | — | US | disclosed |
| EP-1198554-A2 | DETECTION OF MICRO-ORGANISMS | FSM Technologies Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
| WO-2002009677-A2 | METHOD TO TREAT INFECTIOUS DISEASES AND/OR TO ENHANCE ANTIMICROBIAL EFFICACY OF DRUGS | VIROCELL INC. (CA) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176134-A1 | LIGANDS OF NUCLEAR RECEPTORS PPAR'S | Nuclear Receptor Research Limited (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0666910-B1 | METHOD OF CLEAVING SPECIFIC STRANDS OF RNA | US GOV HEALTH & HUMAN SERV (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1165815-A1 | CHIMERIC EXPRESSION PROMOTERS ORIGINATING FROM COMMELINA YELLOW MOTTLE VIRUS AND CASSAVA VEIN MOSAIC VIRUS | MERISTEM THERAPEUTICS (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1163351-A1 | CHIMERIC PROMOTERS BASED ON THE PLASTOCYANIN PETE PROMOTER FROM PEA | MERISTEM THERAPEUTICS (FR) | 2001-12-19 | — | — | EP | disclosed |
| EP-1153138-A1 | DETECTION OF CELLS USING THE LUCIFERASE/LUCIFERIN REACTION | PROMEGA CORPORATION (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-0688360-B1 | BONE STIMULATING FACTOR | OSTEOPHARM INC (CA) | 2001-11-14 | — | — | EP | disclosed |
| EP-1147188-A1 | INTERNAL RIBOSOME ENTRY SITE (IRES), VECTOR CONTAINING SAME AND THE USES THEREOF | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2001-10-24 | — | — | EP | disclosed |
| EP-1142870-A1 | NOVEL LIGANDS OF NUCLEAR RECEPTOR | Nuclear Receptor Research Limited (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6300093-B1 | AN ISOLATED POLYNUCLEOTIDE ENCODING A MACAQUE ISLET CELL ANTIGEN POLYPEPTIDE THAT FORMS AN IMMUNE COMPLEX WITH AN AUTOANTIBODY FROM PATIENTS AT RISK FOR INSULIN-DEPENDENT DIABETES MELLITUS; THRAPY AND DIAGNOSIS | ZYMOGENETICS, INC. | 2001-10-09 | — | — | US | disclosed |
| US-6297284-B1 | AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2001-10-02 | — | — | US | disclosed |
| WO-2001070217-A1 | DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-09-27 | — | — | WO | disclosed |
| CN-1313766-A | Novel DNA-cleaving antitumor agents | RES EDVELOPMENT FOUNDATION (US) | 2001-09-19 | — | — | CN | disclosed |
| US-6271369-B1 | OLIGONUCLEOTIDES WHICH TARGET MIRCOORGANISM TRANSCRIPTS; FOR THE TREATMENT OF VIRAL DISEASE AND CANCER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-08-07 | — | — | US | disclosed |
| US-6271348-B1 | FUSION PROTEIN WHICH INHIBITS TRANSCRIPTION IN EUKARYOTIC CELLS; FOR USE AS A TOOL IN GENE REGULATION | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| EP-1120466-A2 | Use of negative regulation elements for nerve-specific expression of transgenes | Aventis Pharma S.A. (FR) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001053817-A2 | METHODS OF AND APPARATUS FOR SEPARATING AND DETECTING NUCLEIC ACID | MOSAIC TECHNOLOGIES (US) | 2001-07-26 | — | — | WO | disclosed |
| US-20010008026-A1 | SYSTEM FOR TISSUE-RESTRICTED GENE RECOMBINATION | BAYLOR COLLEGE OF MEDICINE | 2001-07-12 | — | — | US | disclosed |
| WO-2001045700-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045711-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1109552-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6252136-B1 | GENETICALLY ENGINEERED PLANT; FOR THE CONTROL OF GENE EXPRESSION IN CELLS; FOR TREATMENT OF ARTHRITIS AND INFLAMMATION; WOUND HEALING; FOR TREATMENT OF CANCER; GENE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| EP-1107665-A1 | METHOD OF DIAGNOSIS OF PROSTATE CANCER | Uropath PTY. Ltd. (AU) | 2001-06-20 | — | — | EP | disclosed |
| EP-1105428-A1 | NOVEL CLEAVED FRAGMENTS OF FIBRINOGEN | THE NEW YORK BLOOD CENTER, INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6242667-B1 | PLANT HAVING TRANSCRIPTIONAL REGULATORY SEQUENCE LINKED TO POLYNUCLEOTIDE ENCODING A FUSION PROTEIN OF A MUTATED TET REPRESSOR AND A TRANSCRIPTION ACTIVATOR; FUSION PROTEIN ACTIVATES TRANSCRIPTION OF A TET OPERATOR LINKED GENE | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| WO-2001037780-A2 | UROTENSIN-II ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001037856-A1 | UROTENSIN-II CYCLIC ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1092771-A2 | Tetracycline-regulated transcriptional modulators | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-18 | — | — | EP | disclosed |
| US-6214805-B1 | GENES, GENE SIGNALS, GENOMES RNA STRANDS AND RESPIRATORY SYNCYTIAL VIRUS WITH PROMOTERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-04-10 | — | — | US | disclosed |
| WO-2001023593-A1 | SYNTHETIC AND CHIMERIC PROMOTERS, EXPRESSION CASSETTES, PLASMIDS, VECTORS, TRANSGENIC PLANTS AND SEEDS CONTAINING THEM, AND METHOD FOR PRODUCING THEM | MERISTEM THERAPEUTICS (FR) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001011006-A2 | DETECTION OF MICRO-ORGANISMS | FLUID TECHNOLOGIES PLC (GB) | 2001-02-15 | — | — | WO | disclosed |
| US-6172189-B1 | POLYPEPTIDE FOR THE DETECTION OF ANTIBODIES ASSOCIATED WITH PREFERENTIAL VIRAL DISEASES AND INFECTION | ABBOTT LABORATORIES | 2001-01-09 | — | — | US | disclosed |
| EP-1053341-A1 | USE OF NEGATIVE REGULATION ELEMENTS FOR NERVE-SPECIFIC EXPRESSION OF TRANSGENES | Aventis Pharma S.A. (FR) | 2000-11-22 | — | — | EP | disclosed |
| US-6136954-A | POLYPEPTIDE WHICH ACTIVATES TRANSCRIPTION IN EUCARYOTIC CELLS IN THE PRESENCE OF ANTIBIOTIC; FOR ANALYSIS OF CELLULAR PROTEINS | BASF AKTIENGESELLSCHAFT (US) | 2000-10-24 | — | — | US | disclosed |
| US-6133229-A | STABILIZING AQUEOUS ENZYME WITH AQUEOUS SOLUTION COMPRISING TRIS/HYDROXYMETHYL/METHYL COMPOUND, CATIONIC POLYELECTROLYTE, POLYOL, SALT OF CALCIUM, MAGNESIUM AND/OR COBALT | THE UNIVERSITY OF LEEDS INNOVATIONS, LTD. (GB) | 2000-10-17 | — | — | US | disclosed |
| WO-2000058485-A1 | CHIMERIC EXPRESSION PROMOTERS ORIGINATING FROM COMMELINA YELLOW MOTTLE VIRUS AND CASSAVA VEIN MOSAIC VIRUS | MERISTEM THERAPEUTICS (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000056906-A1 | CHIMERIC PROMOTERS BASED ON THE PLASTOCYANIN PETE PROMOTER FROM PEA | MERISTEM THERAPEUTICS (FR) | 2000-09-28 | — | — | WO | disclosed |
| EP-1033992-A1 | RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS | THE CLEVELAND CLINIC FOUNDATION (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000049171-A1 | DETECTION OF CELLS USING THE LUCIFERASE/LUCIFERIN REACTION | PROMEGA CORPORATION (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000044896-A1 | INTERNAL RIBOSOME ENTRY SITE (IRES), VECTOR CONTAINING SAME AND USES THEREOF | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2000-08-03 | — | — | WO | disclosed |
| US-6096740-A | BLOCK N-METHYL-ASPARTATE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2000-08-01 | — | — | US | disclosed |
| WO-2000003709-A9 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | UNIV TEXAS (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-1007655-A1 | RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0642666-B1 | HEPATITIS C ASSAY | ABBOTT LAB (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000011947-A1 | METHOD OF DIAGNOSIS OF PROSTATE CANCER | UROPATH PTY. LTD. (AU) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000009562-A1 | NOVEL CLEAVED FRAGMENTS OF FIBRINOGEN | THE NEW YORK BLOOD CENTER, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000003709-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2000-01-27 | — | — | WO | disclosed |
| US-6004941-A | INTRODUCING NUCLEIC ACID ENCODING FUSION PROTEIN WHICH ACTIVATES TRANSCRIPTION AND COMPRISES A POLYPEPTIDE THAT BINDS TO TETRACYCLINE OPERATOR | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-21 | — | — | US | disclosed |
| US-5998602-A | RNase L activators and antisense oligonucleotides effective to treat RSV infections | THE CLEVELAND CLINIC FOUINDATION AND GOVERNMENT (US) | 1999-12-07 | — | — | US | disclosed |
| US-5977345-A | PRELOADING BIOPOLYMER BEADS WITH ORGANIC SOLVENT, ADDING BIFUNCTIONAL REAGENT DISSOLVED IN ORGANIC SOLVENT MIXTURE, REACTING ONE FUNCTIONALITY OF REAGENT WITH THE POLYMER; FOR IONIC BINDING SITES PRIMARILY WITHIN INTERIOR | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0472207-B1 | Hepatitis C assay utilizing recombinant antigens | ABBOTT LAB (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5945581-A | GENETIC ENGINEERING | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1999041396-A1 | USE OF NEGATIVE REGULATION ELEMENTS FOR NERVE-SPECIFIC EXPRESSION OF TRANSGENES | AVENTIS PHARMA S.A. (FR) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040930-A1 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES | CENTER FOR BLOOD RESEARCH, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0929683-A1 | DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE | ZymoGenetics, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5922328-A | HERPES SIMPLEX | AVIRON (US) | 1999-07-13 | — | — | US | disclosed |
| US-5922927-A | Methods for producing tetracycline-regulated transgenic mice | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0925369-A1 | UNIVERSAL TEST SYSTEMS AND METHODS OF USE THEREOF FOR IDENTIFYING MULTIPLE FAMILIES OF MICROORGANISMS | Dade Microsan Inc. (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5912411-A | Mice transgenic for a tetracycline-inducible transcriptional activator | UNIVERSITY OF HEIDELBERG (DE) | 1999-06-15 | — | — | US | disclosed |
| WO-1999022742-A1 | RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS | THE CLEVELAND CLINIC FOUNDATION (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5888760-A | COMBINATION OF NON-REDUNDANT TESTS IN REACTION CHAMBERS CONTAINING SUBSTRATES FOR ENZYMATIC CLASSIFICATION BY DETECTION OF FLUORESCENT OR COLORIMETRIC PRODUCTS FORMED | DADE MICROSCAN INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5888981-A | INTRODUCING INTO CELL A NUCLEIC ACID MOLECULE ENCODING A TETRACYCLINE-CONTROLLABLE TRANSACTIVATOR COMPRISING A TET REPRESSOR OPERABLY LINKED TO A POLYPEPTIDE WHICH ACTIVATES TRANSCRIPTION IN EUCARYOTIC CELLS, MODULATING CONCENTRATION | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-30 | — | — | US | disclosed |
| US-5866755-A | Animals transgenic for a tetracycline-regulated transcriptional inhibitor | BASF AKTIENGELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| US-5859310-A | Mice transgenic for a tetracycline-controlled transcriptional activator | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-12 | — | — | US | disclosed |
| US-5854010-A | Bioassay for detecting 2,3,7,8-tetrachlorodibenzo-para-dioxin and TCDD-like compounds and novel recombinant cell line useful therefor | XENOBIOTIC DETECTION SYSTEMS INTERNATIONAL, INC. | 1998-12-29 | — | — | US | disclosed |
| US-5850025-A | Protection of plants against plant pathogens | SIBIA NEUROSCIENCES, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0760099-A4 | METHOD AND REAGENTS USEFUL FOR IMPROVING IMMUNOASSAY SPECIFICITY | ABBOTT LAB (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998045469-A1 | UNIVERSAL TEST SYSTEMS AND METHODS OF USE THEREOF FOR IDENTIFYING MULTIPLE FAMILIES OF MICROORGANISMS | DADE MICROSCAN INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5814618-A | TETRACYCLINE-RESPONSIVE FUSION PROTEINS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-29 | — | — | US | disclosed |
| EP-0649905-B1 | Methods of detection of mutagens using luminescence gene | TOYODA CHUO KENKYUSHO KK (JP) | 1998-09-23 | — | — | EP | disclosed |
| US-5789156-A | NUCLEIC ACIDS ENCODING FUSION PROTEINS WHICH INHIBITSTRANSCRIPTION OF EUKARYOTIC CELLS | BASF AG (DE) | 1998-08-04 | — | — | US | disclosed |
| WO-1997009999-A9 | METHODS AND COMPOSITIONS FOR TREATMENT OF HSV-2 INFECTIONS AND CONDITIONS | — | 1997-11-06 | — | — | WO | disclosed |
| EP-0804565-A1 | TETRACYCLINE-REGULATED TRANSCRIPTIONAL MODULATORS | Bujard, Hermann (DE) | 1997-11-05 | — | — | EP | disclosed |
| US-5677289-A | ANTIBODY OLIGONUCLEOTIDE | THE CLEVELAND CLINIC FOUNDATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997032984-A1 | DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE | ZYMOGENETICS, INC. (US) | 1997-09-12 | — | — | WO | disclosed |
| US-5665579-A | TRANSGENIC TOMATO PLANTS GENETICALLY ENGINEERED | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997029757-A1 | RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5654168-A | ISOLATED NUCLEIC ACID ENCODING FUSION PROTEIN COMPRISING FIRST POLYPEPTIDE WHICH BINDS TO TET OPERATOR SEQUENCE IN PRESENCE OF TETRACYCLINE OPERATIVELY LINKED TO SECOND POLYPEPTIDE WHICH ACTIVATES TRANSCRIPTION IN EUKARYOTIC CELLS | BASF AKTIENGESELLSCHAFT (DE) | 1997-08-05 | — | — | US | disclosed |
| US-5650298-A | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| US-5637466-A | Method of detecting bone acidic glycoprotein-75 and its 50,000 MW fragment and antibodies therefor | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1997-06-10 | — | — | US | disclosed |
| US-5633449-A | A DNA MOLECULE | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5618927-A | INCUBATION IN SOLUTION OF TRIS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| WO-1997009999-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HSV-2 INFECTIONS AND CONDITIONS | AVIRON (US) | 1997-03-20 | — | — | WO | disclosed |
| EP-0760099-A1 | METHOD AND REAGENTS USEFUL FOR IMPROVING IMMUNOASSAY SPECIFICITY | ABBOTT LABORATORIES (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5589362-A | FUSION PROTEINS, EUKARYOTIC CELLS | BASF AKTIENGESELLSCHAFT (DE) | 1996-12-31 | — | — | US | disclosed |
| US-5589104-A | Electrophoresis separation gel and a method for preparing an electrophoresis separation gel | BAMBECK GREGORY S (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1996040892-A1 | TETRACYCLINE REGULATED TRANSCRIPTIONAL MODULATORS WITH ALTERED DNA BINDING SPECIFICITIES | BASF AG (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5583032-A | USING A CHIMERIC MOLECULE MADE UP OF AN ANTISENSE OLIGONUCLEOTIDE ATTACHED TO A 2',5'-OLIGOADENYLATE MOLECULE; ANTISENSE OLIGONUCLEOTIDE IS HYBRIDIZED TO SENSE STRAND OF RNA IN PRESENCE OF 2',5'-DEPENDENT RNASE | THE CLEVELAND CLINIC FOUNDATION AND NATIONAL INSTITUTES OF HEALTH (US) | 1996-12-10 | — | — | US | disclosed |
| US-5576428-A | GENETIC EGINEERING | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0647277-A4 | METHODS FOR USING CKS FUSION PROTEINS. | ABBOTT LAB (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0722492-A1 | STABILISATION OF PROTEINS IN SOLUTION | The University of Leeds Innovations Ltd. (GB) | 1996-07-24 | — | — | EP | disclosed |
| US-5532166-A | CAPILLARY ZONE ELECTROPHORESIS WITH LASER-EXCITED FLUORESCENCE DETECTION | MA YINFA (US) | 1996-07-02 | — | — | US | disclosed |
| US-5521215-A | TREATMENT OF NERVOUS SYSTEM INJURIES | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1996-05-28 | — | — | US | disclosed |
| EP-0705334-A1 | TIGHT CONTROL OF GENE EXPRESSION IN EUCARYOTIC CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS | BASF AKTIENGESELLSCHAFT (DE) | 1996-04-10 | — | — | EP | disclosed |
| JP-H0849282-A | TOILET OF FIRE RETARDANT RESIN | TOKUYAMA CORP | 1996-02-20 | — | — | JP | disclosed |
| WO-1996001313-A1 | TETRACYCLINE-REGULATED TRANSCRIPTIONAL MODULATORS | BUJARD HERMANN (DE) | 1996-01-18 | — | — | WO | disclosed |
| WO-1995030902-A1 | METHOD AND REAGENTS USEFUL FOR IMPROVING IMMUNOASSAY SPECIFICITY | ABBOTT LABORATORIES (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5464758-A | Polynucleotide molecule codes for eukarotic proteins | TET SYSTEMS HOLDING GMBH & CO. KG (DE) | 1995-11-07 | — | — | US | disclosed |
| EP-0673423-A1 | VIRAL RESISTANCE BY PLANT TRANSFORMATION WITH A REPLICASE PORTION OF A PLANT VIRUS GENOME | CORNELL RESEARCH FOUNDATION, INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0445423-B1 | Hepatitis C assay | ABBOTT LAB (US) | 1995-09-20 | — | — | EP | disclosed |
| EP-0666910-A1 | METHOD OF CLEAVING SPECIFIC STRANDS OF RNA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-16 | — | — | EP | disclosed |
| US-5422108-A | Applying lysozyme which digests cell walls of microbes under acidic conditions | SMART PLANTS INTERNATIONAL INC. (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0612207-A4 | PROTECTION OF PLANTS AGAINST PLANT PATHOGENS. | SMART PLANTS INT INC (US) | 1995-05-24 | — | — | EP | disclosed |
| EP-0673423-A4 | VIRAL RESISTANCE BY PLANT TRANSFORMATION WITH A REPLICASE PORTION OF A PLANT VIRUS GENOME. | CORNELL RES FOUNDATION INC (US) | 1995-05-23 | — | — | EP | disclosed |
| EP-0649905-A1 | Methods of detection of mutagens using luminescence gene | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995010605-A1 | STABILISATION OF PROTEINS IN SOLUTION | THE UNIVERSITY OF LEEDS INNOVATIONS LTD. (GB) | 1995-04-20 | — | — | WO | disclosed |
| EP-0647277-A1 | METHODS FOR USING CKS FUSION PROTEINS | ABBOTT LABORATORIES (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0642666-A1 | HEPATITIS C ASSAY | ABBOTT LABORATORIES (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0600009-A4 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO NS1. | ABBOTT LAB (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0600018-A4 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO C-100 REGION. | ABBOTT LAB (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0600000-A4 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS FROM NS5 REGION. | ABBOTT LAB (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994029442-A2 | TIGHT CONTROL OF GENE EXPRESSION IN EUCARYOTIC CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-22 | — | — | WO | disclosed |
| EP-0642666-A4 | HEPATITIS C ASSAY. | ABBOTT LAB (US) | 1994-11-22 | — | — | EP | disclosed |
| EP-0612207-A1 | PROTECTION OF PLANTS AGAINST PLANT PATHOGENS | SMART PLANTS INTERNATIONAL, INC. (US) | 1994-08-31 | — | — | EP | disclosed |
| US-5330893-A | Use of superoxide dismutase in specimen diluent | ABBOTT LABORATORIES (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0568639-A4 | USE OF SUPEROXIDE DISMUTASE IN SPECIMEN DILUENT | ABBOTT LAB (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5322769-A | Detecting anti-analyte antibody in test sample; kits | ABBOTT LABORATORIES (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0600000-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS FROM NS5 REGION | ABBOTT LABORATORIES (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600009-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO NS1 | ABBOTT LABORATORIES (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600018-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO C-100 REGION | ABBOTT LABORATORIES (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1994009129-A2 | METHOD OF CLEAVING SPECIFIC STRANDS OF RNA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994000594-A9 | METHODS FOR USING CKS FUSION PROTEINS | — | 1994-03-17 | — | — | WO | disclosed |
| WO-1994000594-A1 | METHODS FOR USING CKS FUSION PROTEINS | ABBOTT LABORATORIES (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993025068-A1 | VIRAL RESISTANCE BY PLANT TRANSFORMATION WITH A REPLICASE PORTION OF A PLANT VIRUS GENOME | CORNELL RESEARCH FOUNDATION, INC. (US) | 1993-12-23 | — | — | WO | disclosed |
| EP-0573566-A1 | NOVEL INVERTASE GENE(S) AND USES THEREOF | SIBIA NEUROSCIENCES, INC. (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0304151-B1 | Measurement of calcium ions | INSTRUMENTATION LAB SPA (IT) | 1993-12-15 | — | — | EP | disclosed |
| EP-0568639-A1 | USE OF SUPEROXIDE DISMUTASE IN SPECIMEN DILUENT | ABBOTT LABORATORIES (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1993006247-A1 | HEPATITIS C ASSAY | ABBOTT LABORATORIES (US) | 1993-04-01 | — | — | WO | disclosed |
| WO-1993005645-A1 | PROTECTION OF PLANTS AGAINST PLANT PATHOGENS | SMART PLANTS INTERNATIONAL, INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| WO-1993004087-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO C-100 REGION | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004088-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO NS1 | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004089-A1 | HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS FROM NS5 REGION | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5160739-A | Moisture cream, cleanser, polyolefins, polyoxyalkylene glycol solubilizer | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1992-11-03 | — | — | US | disclosed |
| WO-1992014831-A1 | NOVEL INVERTASE GENE(S) AND USES THEREOF | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992013275-A1 | USE OF SUPEROXIDE DISMUTASE IN SPECIMEN DILUENT | ABBOTT LABORATORIES (US) | 1992-08-06 | — | — | WO | disclosed |
| US-5135748-A | Quaternary ammonium functionalized phosphate ester | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0472207-A2 | Hepatitis C assay utilizing recombinant antigens | ABBOTT LABORATORIES (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5061336-A | GEL CASTING METHOD AND APPARATUS | SOANE TECHNOLOGIES, INC. (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0445423-A2 | Hepatitis C assay | ABBOTT LABORATORIES (US) | 1991-09-11 | — | — | EP | disclosed |
| US-5045465-A | Culturing flavobacterium, a-ketoglutaric acid, ammonium sulfate | EASTMAN KODAK COMPANY (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0427845-A4 | GEL CASTING METHOD AND APPARATUS | — | 1991-07-10 | — | — | EP | disclosed |
| EP-0427845-A1 | GEL CASTING METHOD AND APPARATUS | SOANE, David S. (US) | 1991-05-22 | — | — | EP | disclosed |
| US-5017489-A | Antibodies | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0413285-A2 | Fermentation process for creatinine iminohydrolase | EASTMAN KODAK COMPANY (US) | 1991-02-20 | — | — | EP | disclosed |
| WO-1990014201-A1 | GEL CASTING METHOD AND APPARATUS | SOANE DAVID S (US) | 1990-11-29 | — | — | WO | disclosed |
| EP-0363083-A2 | Pharmaceutical preparation for treatment of thrombocytopenic or platelet function-deficient disease | Chugai Seiyaku Kabushiki Kaisha (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4880751-A | Immunoglobulin adsorption | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-11-14 | — | — | US | disclosed |
| US-4870024-A | DILUTION WITH TRIS PHOSPHATE | FISHER SCIENTIFIC COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| US-4859342-A | Process for industrially separating biopolymers | SUNTORY LIMITED (JP) | 1989-08-22 | — | — | US | disclosed |
| EP-0304151-A2 | Measurement of calcium ions | INSTRUMENTATION LABORATORY S.p.A. (IT) | 1989-02-22 | — | — | EP | disclosed |
| EP-0254593-A2 | Preparation and uses of interferon-gamma | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1988-01-27 | — | — | EP | disclosed |
| EP-0211756-A1 | Assay for varicella-zoster virus (VZV) antibodies | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4603108-A | Method for identification of bacterial species | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-07-29 | — | — | US | disclosed |
| EP-0029766-B1 | METHOD FOR THE RECOVERY OF CREATININE IMINOHYDROLASE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4432877-A | Organo-mercurial materials | NEW ENGLAND NUCLEAR CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4409275-A | Decorative laminate | SAMOWICH JOSEPH J | 1983-10-11 | — | — | US | disclosed |
| US-4275166-A | PRECIPITATING CREATINE IMINOHYDROLASE | EASTMAN KODAK COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
| EP-0029766-A1 | Method for the recovery of creatinine iminohydrolase | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4252896-A | Method of stabilizing peroxidase in a serum protein based medium | ABBOTT LABORATORIES (US) | 1981-02-24 | — | — | US | disclosed |
| WO-1980002433-A1 | THE IDENTIFICATION OF BACTERIA | NAT RES DEV (GB) | 1980-11-13 | — | — | WO | disclosed |
| EP-0018825-A1 | A process for the identification of bacteria and a kit of reagents for use in this process | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1980-11-12 | — | — | EP | disclosed |
| US-4170614-A | HYDROLYSIS OF TRIS(2,6-DIHALOPHENYL) PHOSPHATE | PPG INDUSTRIES, INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4059655-A | REACTING A 2,6-DIHALOPHENOL WITH PHOSPHORUS OXYHALIDE, HYDROLYSIS | PPG INDUSTRIES, INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4059655-A | REACTING A 2,6-DIHALOPHENOL WITH PHOSPHORUS OXYHALIDE, HYDROLYSIS | PPG INDUSTRIES, INC. (US) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100580-A1 | Urotensin-II receptor antagonists | UTS2R, TMPRSS4, PLAUR | DNMT1 4879/4885MAPT 3109/4885HTT 2297/4885 |
| US-20140113944-A1 | BICYCLO (3.1.0) HEXANE-2, 6-DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | GRM2, GRIA2, HCAR2 | DNMT1 2863/4885MAPT 1470/4885HTT 2746/4885 |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | DNMT1 2390/4885MAPT 1299/4885HTT 2416/4885 |
| US-10202325-B2 | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols | TTPA, GSTO1, TST | DNMT1 1844/4885MAPT 4123/4885HTT 2651/4885 |
| US-20140288185-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE MODULATORS | CHRNA5, CHRNG, CHRNA2 | DNMT1 4014/4885MAPT 2378/4885HTT 1416/4885 |
| US-20040142923-A1 | Pyrrolidine sulfonamides | UTS2R, PRSS2, PRSS8 | DNMT1 4870/4885MAPT 2548/4885HTT 1085/4885 |
| US-10258582-B2 | Nicotinic receptor non-competitive antagonists | CHRNA5, CHRNA2, CHRNG | DNMT1 4153/4885MAPT 2694/4885HTT 1373/4885 |
| US-20130245273-A1 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP4K5, MAP3K5, MAP3K20 | DNMT1 3254/4885MAPT 1042/4885HTT 1296/4885 |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | DNMT1 412/4885MAPT 695/4885HTT 337/4885 |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | DNMT1 4700/4885MAPT 46/4885HTT 19/4885 |
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | ESR1, CYP19A1, GPER1 | DNMT1 3074/4885MAPT 2091/4885HTT 1754/4885 |
| US-20180319730-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | TTPA, GSTO1, TST | DNMT1 1844/4885MAPT 4123/4885HTT 2651/4885 |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | DNMT1 4099/4885MAPT 3119/4885HTT 4133/4885 |
| US-20150258099-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | ESR1, ESRRG, ESR2 | DNMT1 1106/4885MAPT 4151/4885HTT 3235/4885 |
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | FGF1, FGFR1, FGF2 | DNMT1 4844/4885MAPT 1768/4885HTT 2624/4885 |
| US-20110046104-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | DNMT1 1384/4885MAPT 954/4885HTT 2296/4885 |
| US-11596669-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | FGF1, FGFR1, FGF2 | DNMT1 4844/4885MAPT 1768/4885HTT 2624/4885 |
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKCH, DMPK, MAP3K20 | DNMT1 3043/4885MAPT 839/4885HTT 274/4885 |
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | DNMT1 2390/4885MAPT 1299/4885HTT 2416/4885 |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | DNMT1 3851/4885MAPT 570/4885HTT 2902/4885 |
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | DNMT1 3556/4885MAPT 830/4885HTT 964/4885 |
| US-20130310433-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, PACSIN2 | DNMT1 3862/4885MAPT 1217/4885HTT 1109/4885 |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | IL4, IL4I1, STAT4 | DNMT1 3311/4885MAPT 2047/4885HTT 2627/4885 |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | ATR, MAP3K5, CHEK1 | DNMT1 1729/4885MAPT 3129/4885HTT 2299/4885 |
| US-20210275557-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | FBL, MRPL21, NOP2 | DNMT1 1788/4885MAPT 4715/4885HTT 3293/4885 |
| US-20030022934-A1 | Phenoxyphenyl alkanesulphonates | SNCA, CLN6, NLN | DNMT1 3981/4885MAPT 49/4885HTT 7/4885 |
| US-20110152334-A1 | MGLU2 AGONISTS | GRM2, GRIA2, GRM4 | DNMT1 1812/4885MAPT 1331/4885HTT 2496/4885 |
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | DNMT1 1428/4885MAPT 1503/4885HTT 1791/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | DNMT1 412/4885MAPT 695/4885HTT 337/4885 |
| US-20230338471-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | FGF1, FGFR1, FGF2 | DNMT1 4844/4885MAPT 1768/4885HTT 2624/4885 |
| US-20160008323-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | CHRNA5, CHRNA2, CHRNG | DNMT1 4153/4885MAPT 2694/4885HTT 1373/4885 |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | MET, PRKCH, DMPK | DNMT1 1623/4885MAPT 1158/4885HTT 1414/4885 |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | MAP3K1, MAP3K20, MAP3K2 | DNMT1 2528/4885MAPT 775/4885HTT 789/4885 |
| US-20120232275-A1 | PROCESS FOR PREPARING 5-FLUORO-1H-PYRAZOLO [3,4-B] PYRIDIN-3-AMINE AND DERIVATIVES THEREOF | GSK3B, GSK3A, GSKIP | DNMT1 1272/4885MAPT 529/4885HTT 4662/4885 |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | DNMT1 1574/4885MAPT 2916/4885HTT 2185/4885 |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | DNMT1 1376/4885MAPT 1754/4885HTT 1997/4885 |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | DNMT1 3556/4885MAPT 830/4885HTT 964/4885 |
| US-20170297991-A1 | METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS | TTPA, GSTO1, TST | DNMT1 2139/4885MAPT 4272/4885HTT 2484/4885 |
| US-20180271806-A1 | NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS | CHRNA5, CHRNA2, CHRNG | DNMT1 4153/4885MAPT 2694/4885HTT 1373/4885 |
| US-20160090378-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | DNMT1 3956/4885MAPT 3601/4885HTT 4589/4885 |
| US-20040054162-A1 | Molecular detection systems utilizing reiterative oligonucleotide synthesis | POLRMT, RNGTT, POLI | DNMT1 91/4885MAPT 4415/4885HTT 2570/4885 |
| US-20040152891-A1 | Sulfonamides | UTS2R, PRSS2, STS | DNMT1 4883/4885MAPT 2260/4885HTT 1651/4885 |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | PRKCH, DMPK, MAP3K20 | DNMT1 3043/4885MAPT 839/4885HTT 274/4885 |
| US-20040198979-A1 | Sulfonamides | UTS2R, PRSS2, STS | DNMT1 4883/4885MAPT 2260/4885HTT 1651/4885 |
| US-20040002117-A1 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | NFATC1, CHP1, PPP3R1 | DNMT1 4564/4885MAPT 3702/4885HTT 2665/4885 |
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, MAP3K5, MAP3K20 | DNMT1 1331/4885MAPT 1628/4885HTT 1887/4885 |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | DNMT1 1428/4885MAPT 1503/4885HTT 1791/4885 |
| US-20080070965-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, MAP3K5, PACSIN2 | DNMT1 3862/4885MAPT 1217/4885HTT 1109/4885 |
| US-20100184980-A1 | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof | GSK3B, GSK3A, GSKIP | DNMT1 1272/4885MAPT 529/4885HTT 4662/4885 |
| US-20140037754-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | DNMT1 1384/4885MAPT 954/4885HTT 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.